Published in final edited form as:

Bioorg Med Chem. 2017 December 01; 25(23): 6248–6265. doi:10.1016/j.bmc.2017.03.061.

An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors

Nicholas Pagano^{a,1}, Peter Teriete^{a,1}, Margrith E. Mattmann^a, Li Yang^a, Beth A. Snyder^b, Zhaohui Cai^b, Marantha L. Heil^b, and Nicholas D.P. Cosford^{a,*}

^aCancer Metabolism & Signaling Networks Program, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Rd., La Jolla, CA 92037, United States

^bSouthern Research Institute, Drug Development Division, 431 Aviation Way, Frederick, MD 21701, United States

Abstract

Continuous flow (microfluidic) chemistry was employed to prepare a small focused library of dihydropyrimidinone (DHPM) derivatives. Compounds in this class have been reported to exhibit activity against the human immunodeficiency virus (HIV), but their molecular target had not been identified. We tested the initial set of DHPMs in phenotypic assays providing a hit (**1i**) that inhibited the replication of the human immunodeficiency virus HIV in cells. Flow chemistry-driven optimization of **1i** led to the identification of HIV replication inhibitors such as **1l** with cellular potency comparable with the clinical drug nevirapine (NVP). Mechanism of action (MOA) studies using cellular and biochemical assays coupled with 3D fingerprinting and *in silico* modeling demonstrated that these drug-like probe compounds exert their effects by inhibiting the viral reverse transcriptase polymerase (RT). This led to the design and synthesis of the novel DHPM **1at** that inhibits the replication of drug resistant strains of HIV. Our work demonstrates that combining flow chemistry-driven analogue refinement with phenotypic assays, *in silico* modeling and MOA studies is a highly effective strategy for hit-to-lead optimization applicable to the discovery of future therapeutic agents.

Keywords

Flow chemistry; Microreactors; Multistep synthesis; HIV; NNRTI; Resistant virus activity; Dihydropyrimidinone

1. Introduction

In broad terms the process of drug discovery can be separated into two different but well-defined approaches. The target-based approach consists of identifying a suitable protein target and screening chemical libraries of small molecules against this target to identify hits

*Corresponding author. ncosford@sbpdiscovery.org (N.D.P. Cosford).

¹These authors contributed equally.

A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2017.03.061>.

that may be optimized into drugs. The phenotypic drug discovery approach involves screening in cells or organisms where the target is unknown and the mechanism of action (MOA) of active compounds is deduced later through a process of deconvolution. More recently the use of targeted compound libraries based on so-called “privileged” scaffolds that are known to have biological activity against one target class have been used to screen against other targets to identify hits.^{2–9} All of these approaches are either target-based or phenotype-based and originate in searches for small molecule therapeutic agents for a specific disease, as discussed in detail by Schenone and colleagues.⁶ We have refined a different approach. Our compound-centric methodology that starts with highly promising scaffolds, identifies a putative therapeutic area where these scaffolds may prove beneficial, and subsequently identifies a molecular target for the compound action. We have exemplified this novel strategy to generate new classes of bio-active compounds based on our ability to rapidly generate diverse dihydropyrimidinone (DHPM) derivatives.¹⁰

DHPMs are well known as privileged scaffolds that exhibit favorable therapeutic and pharmacological properties across a range of bioactivities in approved drugs.^{11,12} A comprehensive analysis of published bioactivities of DHPMs with some similarity to our derivatives led us to investigate activity against human immunodeficiency virus (HIV),¹³ a therapeutic target that is amenable to phenotypic screening. HIV is the causative agent of acquired immunodeficiency syndrome (AIDS), a disease for which there is no cure. Currently, more than 1.1 million people in the USA are living with HIV infection. The prevalence of HIV/AIDS is on the rise with about 50,000 new infections each year in the USA alone. The cost of these new cases is estimated to be around \$36.4 billion, comprised of both direct medical costs (\$6.7 billion) and loss of productivity (\$29.7 billion).¹⁴ A comprehensive analysis of the contemporary cost of HIV healthcare by Gebo and colleagues concluded: “*HIV healthcare in the United States continues to be expensive, with the majority of expenditures attributable to medications. With improved HIV survival, costs may increase and should be monitored in the future.*”^[15] Despite the fact that there are over 25 FDA approved drugs for the treatment of HIV,¹⁶ the well-documented ability of the virus to acquire resistance against established methods of treatment requires the development of novel drug classes. There is therefore an ongoing significant need to investigate probe molecules that could ultimately lead to drugs with the capacity to overcome such resistance.^{17,18}

Herein we describe how screening a focused library of small molecule compounds in a phenotypic assay coupled with flow chemistry-driven hit-to-lead optimization, comprehensive database searching and computational modeling led to the prediction and subsequent identification of the MOA for a novel series of HIV replication inhibitors. Our efficient approach to target identification and validation may provide the basis for an expanded drug discovery program.

2. Results and discussion

We recently reported a highly efficient continuous flow method for the synthesis of substituted dihydropyrimidinone (DHPM) derivatives (**1**).¹⁰ Our methodology provides access to a scaffold with favorable drug-like characteristics and allows the generation of

highly varied analogues. The compounds prepared in this way are structurally related to thiazole derivatives such as compound **2** that were initially disclosed in a patent application and subsequently reported in the scientific literature (Fig. 1).¹³ We were intrigued by the physical similarity between our DHPM derivatives and the related structures **2**, which were described to possess inhibitory activity toward HIV replication in cells, although no MOA has been reported.¹³ We therefore designed a biological testing funnel to narrow down the target of the DHPMs (Fig. 2). We initiated target identification studies by comparing antiviral activity in two commonly used phenotypic screens. The MAGI-CCR5 antiviral assay is a single round antiviral assay employing the MAGI-CCR5 reporter cell line that produces low levels of virus. In this assay, the virus produced in an infected cell does not infect neighboring cells. MAGI-CCR5 cells can therefore be used to assess the MOA of compounds that are active early in the replication cycle, such as entry or viral reverse transcriptase polymerase (RT) inhibitors. We utilized peripheral blood mononuclear cells (PBMC) in a multi-round assay as the comparator assay.¹⁹ In contrast to a single-round assay, in the PBMC assay the neighboring cells are infected by the progeny virions produced from the initial infection. Using control compounds as a reference, a difference of greater than two-fold activity was required in order to convince us that the activity was localized to early steps in the replication cycle. The result of this dual assay approach allowed for the confirmation of antiviral activity while already narrowing the MOA. We tested an initial set of analogues in cellular antiviral assays measuring HIV replication alongside cytotoxicity prior to advancing to more in-depth and costly secondary studies to identify the MOA. The data generated from the first set of compounds prompted us to investigate the SAR in more detail utilizing the already established phenotypic assay and led to a new series of potent HIV replication inhibitors with drug-like properties. The most promising compound was analyzed relative to known HIV inhibitors and a hypothesis was generated that the DHPM target was the HIV RT. Molecular modeling studies along with target specific biological assays confirmed this hypothesis. Our approach to the discovery, rapid SAR and characterization of a series of new HIV replication inhibitors is described in detail below.

2.1. Library construction

The multistep microfluidic synthesis of DHPM analogues **1** is shown in Scheme 1.¹⁰ At the outset of our experiments, we elected to first vary the α -bromoketones **4** to investigate the effects of changing the thiazole R¹ substituent while keeping the DHPM R² substituent constant (*i.e.* R² = 3-hydroxyphenyl). Thus, 0.75 M solutions of thioamide **3** and α -bromoketones **4** in DMF were pumped (32.5 μ L/min) into a 250 μ L reactor heated to 150 °C for 3.75 min. The stream exiting the first microreactor containing each newly constructed ketothiazole intermediate **7** was introduced to a separate stream (32.5 μ L/min) of 3-hydroxybenzaldehyde **5a** and urea (**6a**, R³ = H) (0.90 M, DMF). The combined flow of reactants (97.5 μ L/min) was pumped into a 1000 μ L reactor heated at 200 °C to generate new DHPM derivatives (**1a–1k**). Overall, the continuous two-chip microfluidic sequence required less than one hour for completion from start to finish (injection, reaction, and 1250 μ L collection). The yields for the three-step (thiazole formation/deprotection/Biginelli reaction), two-chip sequence were high (39–48%) (Table 1) and provided sufficient quantities of compounds **1a–1k** for characterization and evaluation in cellular antiviral assays (Table 1). Of the eleven entries, only the extremely electron poor α -bromoketone **4e**

(4-rifluoromethylphenyl) failed to furnish product using this methodology and thus **1e** was prepared using a one-pot batch procedure using conditions optimized using our flow method (Scheme 2). It is notable that the reaction conditions developed for the flow method translated very successfully into batch mode.

To evaluate the activity of this set of DHPMs, we assessed antiviral activity in the single round MAGI-CCR5 reporter cells and the PBMC assay. The structures of DHPMs **1a–1k** and their antiviral activity against HIV-1_{Ba-L} replication in both MAGI-CCR5 reporter cells and also in PBMCs are presented in Table 1. Compounds that dose-dependently reduced MAGI-CCR5 β -galactoside activity with a therapeutic index (TI) >10 (*i.e.* IC₅₀ <10 μ M and TC₅₀ >100 μ M) were tested along with inactive and sub-optimally active compounds in the PBMC assay to confirm activity and the trend observed in the MAGI-CCR5 assay. For these experiments, the non-nucleoside RT inhibitor (NNRTI) nevirapine (NVP) was used as a reference standard. We observed that the difference in compound activity in the assays was between 2 and 4-fold for most compounds in the series suggesting that the MOA of the DHPM series involved viral pathways and genes associated with virus entry or reverse transcription.

We were pleased to observe that one of our initial compounds, **1i** (4-cyanophenyl), proved to be a sub-micromolar inhibitor with an IC₅₀ value of 0.44 ± 0.03 μ M in the MAGI-CCR5 assay. In fact, when compared to the other compounds in this initial library, **1i** proved to be far superior with one of the lowest IC₉₀ values (2.08 ± 0.32 μ M) as well. In addition, and most encouraging, **1i** maintained high levels of cell viability while exhibiting a satisfactory TI of 231.3 ± 15.9 . This activity of **1i** was confirmed in PBMCs demonstrating specific viral reduction and limited cell toxicity after an extended exposure in culture. Halogen substitution (entries 6–8) also yielded fairly potent compounds (**1f–1h**); however, this was accompanied by increased levels of cellular toxicity. Interestingly, DHPMs bearing hydrogen-bonding functional groups such as methoxy and hydroxy (**1b** and **1c**) were poor inhibitors with IC₅₀ values of 66.4 ± 17.7 μ M and 68.3 ± 3.9 μ M, respectively in MAGI-CCR5 and 29.6 μ M and 39.9 ± 6.9 μ M, respectively in PBMCs. These results are especially notable because the 4-cyanophenyl moiety present in **1i** is significantly different, both sterically and electronically, from the cyclohexyl ring present at the corresponding position of compound **2** (Fig. 1). Thus, we had discovered a previously unidentified structural motif that imparts potent HIV inhibitory activity.

Having discovered an R¹ substituent (4-cyanophenyl) that imparts submicromolar potency, as in **1i**, we next focused our efforts on probing the R² substituent on the DHPM ring. We therefore adopted the same flow-based synthetic protocol above and shown in Scheme 1 but now with variation in the aryl aldehyde component **5**. In addition to exploring different oxo-substituted benzaldehyde precursors, we also wished to investigate whether para-cyano substitution was indeed optimal as well as the effect that *N*-methylation would have on the potency of our compounds by using methylurea (**6b**, R³ = Me). Thus, 0.45 M solutions of thioamide **3** and α -bromoketones **4i** (4-cyanophenyl) or **4l** (3-cyanophenyl) in DMF were pumped (32.5 μ L/min) into a 250 μ L reactor heated to 150 °C for 3.75 min. Then, each newly constructed ketothiazole intermediate **7** was introduced to a separate stream (32.5 μ L/min) of aldehydes **5** and either urea (**6a**, R³ = H) or methylurea (**6b**, R³ = Me) (0.54 M,

DMF). The combined flow (97.5 $\mu\text{L}/\text{min}$) was pumped into a 1000 μL reactor heated to 200 $^{\circ}\text{C}$. Unlike our previous setup (Scheme 1), the concentration of the reaction was lowered due to variable precipitation issues at 0.75 M. The isolated yields for the three-step, two-chip sequence were somewhat modest (22–45%) (Table 2), the poorest results observed when using resonance-donating benzaldehydes (entries 1, 2, 4, 6, and 9). This decrease in multistep efficiency is most likely a result of less favorable imine formation in the Biginelli reaction with the electron-rich aldehydes.

The structures of DHPMs **1l–1w** and their antiviral activity against HIV-1_{Ba-L} in MAGI-CCR5 reporter cells and PBMCs are presented in Table 2. Overall, most benzaldehyde components leading to para-oxygen substituted R^2 moieties yielded compounds with improved levels of potency with IC_{50} values $<0.15\text{ }\mu\text{M}$ (**1l**, **1m**, **1p** and **1q**). We were pleased to observe that only one of these compounds (**1m**) decreased cell viability to any significant extent as measured by the MAGI-CCR5 TC_{50} value. 4-Cyanophenyl substitution proved superior to 3-cyanophenyl substitution, which led to decreased potency and increased toxicity levels (**1t** and **1u**), while methyl substitution at R^3 (**6b**) also provided much poorer inhibitory activity in cells (**1v** and **1w**). Lastly, these data helped us to develop two hypotheses. The first was that relatively bulky R^2 substituents were well tolerated. Both **1p** (phenoxy) and **1q** (benzyloxy) proved to be among our best compounds up to this point. The second was that, at a minimum, a hydrogen-bond acceptor is important for attaining increased levels of potency. The molecular modeling studies described below support both of these ideas.

We next investigated the incorporation of heteroatoms into the aryl substituent R^2 by selecting the appropriate aldehyde building blocks **5**. While we were encouraged by both the potency and toxicity profiles of our best compounds up to this point, the majority of them remained relatively hydrophobic and we therefore aimed to improve the drug-like properties of the scaffold. For the microfluidic synthesis of this set of analogues α -bromoketone **4i** ($\text{R}^1 = 4\text{-cyanophenyl}$) was used in combination with various heteroaryl aldehydes **5**. While the overall yield for this continuous sequence was high (34–46%) (Table 3), only pyridine substitution proved viable under these conditions. Even at decreased reaction concentrations (0.45 M), extended heterocyclic substrates failed to yield products (**1aa–1ad**) and often precipitated within the second microreactor chip. Thus, similar to **1e**, these four compounds were prepared using a one-pot, batch-mode procedure (Scheme 2). Overall, these unfunctionalized heterocycles possessed relatively good potency, with *N*-methylindole **1ad** reaching the nanomolar range with an IC_{50} value of $0.74\text{ }\mu\text{M} \pm 0.17$. Furthermore, only one entry displayed any level of cellular toxicity (**1ac**).

Although the latest round of cellular data (Table 3) suggested that indole derivatives (**1ac** and **1ad**) showed promising HIV inhibitory activity we elected to further investigate additional SAR around the pyridine series. Fortunately, a considerable number of substituted pyridyl aldehydes are commercially available allowing us to access these structures rapidly. Thus we constructed DHPMs **1ae–1as** all from α -bromoketone **4i** ($\text{R}^1 = 4\text{-cyanophenyl}$) and the results along with their antiviral activity against HIV-1 MAGICCR5 cells are presented in Table 4. The overall yield for this three-step, two-chip microfluidic sequence was high (42–64%) with only six examples (entries 6, 10–13, 15) requiring a one-pot batch

preparation due to precipitation inside the microchip. Initially, perhaps most impressive is that all 15 pyridyl entries do not display any measureable levels of cellular toxicity. The combination of the nitrogen heteroatom with either *para* alkoxy- (**1an**) or aryloxy-(**1as**) yielded several sub-micromolar inhibitors.

As mentioned previously, a “one-pot” batch-mode procedure was necessary for the production of certain target DHPMs **1**. Even at reduced concentrations (0.45 M), several reaction sequences suffered from irregular precipitation inside the second microchip. Thus, we developed an in-flask batch procedure to access these compounds and this one-pot process is shown in Scheme 2. Unlike our automated flow procedure, the batch process does not facilitate rapid high-throughput synthesis. However, the batch method does allow us to conduct transformations using heterogeneous conditions at much higher concentrations to target specific analogues as needed. In summary, utilizing alternative methodologies allowed us to quickly access most substitution patterns of interest.

At this stage we had synthesized more than forty DHPMs and tested them extensively in cellular assays measuring the inhibition of HIV replication and found several analogues with submicromolar potency. We next tested some of the most promising compounds to assess their drug-like properties *in vitro* using absorption, distribution, metabolism, and excretion (ADME) assays. The results of these studies are shown in Table 5. Permeability was assessed via a parallel artificial membrane permeability assay that estimates blood brain barrier penetration (BBB-PAMPA). The results suggested that the DHPMs are likely to exhibit poor CNS permeability *in vivo*.²¹ The data for plasma and microsomal stability were very encouraging, with all compounds exhibiting good to excellent parameters. Taken together, the *in vitro* ADME data suggest that compounds in this series are likely to have drug-like properties suitable for *in vivo* proof-of-concept studies.

2.2. Mechanism of action, biological relevance and the *in silico*-guided design of a new inhibitor (**1at**)

Given the potency, ability to rapidly produce derivatives and identification of unique structural motifs, we concluded that molecular modeling and secondary biological studies to identify the direct protein target of the DHPMs were warranted. Comparison of our compounds with the NNRTIs rilpivirine and etravirine using *in silico* modeling suggested some apparent similarities in the structures and possible overlap of pharmacophoric features (Fig. 3; Table 6). We therefore sought experimental confirmation by first probing activity against viruses with mutations in the NNRTI binding pocket followed by assessment of DHPMs binding to the viral RT.

The advent of highly active anti-retroviral therapy (HAART) for the chronic suppression of HIV replication in AIDS patients has dramatically increased the mean survival time and improved the quality of life for individuals infected with HIV. Prophylactic administration of anti-retroviral therapy has been shown to reduce the risk of acquiring an infection in healthy individuals.^{22–29} Furthermore, administration of the anti-retroviral drug nevirapine to pregnant women intrapartum and neonatally has been shown to successfully prevent transmission to infants.³⁰ In an effort to eliminate new infections in children, this treatment was expanded and it is now recommended that HIV infected pregnant women are provided

lifelong anti-retroviral therapy as well as postpartum administration of a single dose of nevirapine or AZT from birth through age 4–6 weeks for the child.^{31–34} In 2012, the prophylactic administration of anti-retroviral therapy was approved for the prevention of infection of healthy individuals at high risk of contracting the disease.³⁵ Now more than ever, millions of infected and uninfected people are relying on lifelong anti-retroviral agents until a sterilizing cure can be identified.

The HIV RT is an RNA-dependent DNA polymerase that transcribes the viral RNA into double-stranded proviral DNA copy. The RT has three functions: (1) transcription of the viral RNA into DNA; (2) cleavage of the viral RNA by Ribonuclease H; and (3) transcription of the second DNA strand. The RT is a heterodimer composed of two subunits p66 and p51. The 440 *N*-terminal amino acids of the p66 subunit functions as the viral polymerase and the C-terminal 120 amino acids function as the ribonuclease. The p51 subunit contains the same 440 *N*-terminal amino acids found in the p66 subunit. NNRTIs are allosteric inhibitors of RT polymerization. Structural studies of RT in complex with NNRTIs reveal that inhibitors bind into a pocket primarily composed of amino acids residues Lys101, Lys103, Tyr181, Tyr188, Phe227, Trp229, and Tyr318.^{1,36–40} NNRTI binding is non-catalytic and non-competitive; therefore, the combination of the small molecule surface contact and flexibility influence the potency of the inhibitors.^{41–44}

Several DHPMs with potent activity in cells and low toxicity were selected for more extensive biological and *in silico* modeling studies. For the biological studies, we tested **1l**, **1m**, **1ad**, **1ae**, **1am**, **1an** and **1ar** against A17, a virus that has amino acid variations at positions 103 and 181 (K103N and Y181C) in the NNRTI binding pocket relative to wild type. The asparagine variation at residue 103 and the cysteine variation at residue 181 are known to alter the non-nucleoside inhibitor binding-pocket sufficiently to disrupt the binding of NNRTIs such as nevirapine. Therefore, loss of antiviral activity against the virus would suggest the DHPM was binding the RT. As shown in Table 7, the K103N and Y181C mutations in the A17 virus greatly affect if not abolish the antiviral activity of the DHPMs tested in cells.

For *in silico* modeling studies, compounds **1i**, **1l**, **1m**, **1y**, **1ad**, **1ae**, **1ai**, and **1an** were docked into the NNRTI binding pocket of wild-type (PDB code 3MEC, 3MEE, 2ZD1) as well as Y181C, K103N (PDB code 4I2Q and 4I2P) mutant forms of the RT to identify other potential interactions between RT and the DHPMs as well as to gain insight into the possible orientation of the scaffold (data not shown).⁴⁵ The results of these studies indicated that the docked poses of the DHPMs aligned well with the orientation of etravirine and rilpivirine in the NNRTI binding pocket, matching the steric alignment performed previously (Fig. 3; Table 6).

A single chiral center in the DHPM structure gives rise to two enantiomers in the racemate. In order to predict differences in activity of each enantiomer we performed another alignment *in silico*, this time taking additional pharmacophoric features into account. The differences between (*R*)-**1i** and (*S*)-**1i** when aligned with rilpivirine are shown in Fig. 4. It is noteworthy here that the steric as well as pharmacophoric alignments for (*R*)-**1i** result in a near identical conformation. Subsequently, both enantiomers were docked into the NNRTI

binding-site of wild type (WT) reverse transcriptase taken from the rilpivirine PDB submission (code 3MEE) (Molegro MVD, Aarhus, Denmark). The resulting poses were ranked based on the docking score and conformational similarity to the alignment in Fig. 4 (Table 8). The results suggest a clear separation of activity between the two enantiomers, with (*R*)-**1i** being strongly favored. In support of these data the relevant amino acid interactions of rilpivirine compared with (*R*)-**1i** within the nonnucleoside binding site of the HIV RT are shown in Fig. 5.

In order to support our mechanistic hypothesis, the activities of selected DHPM derivatives were confirmed in a biochemical RT assay using a method described previously⁴⁶ (Table 9). Using a chiral column, the enantiomers of compound **1i** were separated and individually tested in the MAGI-CCR5 cellular assay. Each enantiomer, (*R*)-**1i** and (*S*)-**1i**, was also evaluated in the PBMC cellular assay and an HIV RT biochemical assay. Compound (*R*)-**1i** was found to inhibit virus replication and polymerization of the HIV RT in a dose-dependent manner whereas (*S*)-**1i** had no activity (Table 9). These results further support our hypothesis that the MOA of the DHPMs is through inhibition of the viral RT at the NNRTI site. The data also support the proposed active conformations for the DHPMs determined by *in silico* modeling. All together, these studies demonstrate that, like nevirapine, the MOA of the DHPMs is through inhibition of the HIV RT and strongly suggest that the NNRTI binding pocket is the site of compound binding.

Further investigation of DHPM poses docked on the crystal structure of WT RT bound to etravirine and rilpivirine respectively (PDB code 3MEC, 3MEE;¹ and PDB code 2ZD1⁴⁷) highlighted several key interactions observed in almost all calculated poses for **1i**, **1l**, **1m**, **1y**, **1ad**, **1ae**, **1ai**, **1am**, and **1an**. First, the carbonyl group of the pyrimidinone ring interacts with the backbone amide of K103 or N103, respectively. Second, the nitrogen in the 5 position of the pyrimidinone forms an interaction with the backbone carbonyl of residue 103, while the nitrogen in the 1-position forms an interaction with the side chain carbonyl of E138 from the p51 subunit. Third, the thiazole ring shows a consistent interaction with the β -methylenes of Y181 and the non-polar side chain of V179. Fourth, the cyanophenyl ring interacts with the NNRTI binding pocket at amino acids Y181, Y188, F227, W229 and V106 (Fig. S1; see Supplementary Data). This part of the NNRTI binding pocket can accommodate reasonably bulky groups, such as the cyclohexyl group in compound **2**. However, the planar shape of the phenyl ring in our series of DHPMs adds an additional π -stacking interaction with the aromatic side chain of Y188, while the polar property of the cyano group in the 4-position can contribute through its interaction with the solvent space in the DNA binding groove. Comparing this to etravirine and rilpivirine bound to the same structures it is evident that the bulk of the DHPM binding is driven by ligand to backbone interactions. Upon closer investigation, we concluded that the NNRTI binding pocket could be further filled by introduction of a methyl group on the 4-cyanophenyl moiety of the DHPM. We postulated that this methyl group would interact with the β -methylenes of tyrosine 183 and tryptophan 229 enabling the compound to bind to the RT with some possible variations at the residues in these positions. Based on the *in silico* modeling studies 3-methyl-4-(2-(6-methyl-4-(1-methyl-1H-indol-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl) benzonitrile (**1at**) was synthesized. Thus, as shown in Scheme 3, the

preparation of 4-acetyl-3-methylphenyl trifluoromethanesulfonate from 1-(4-hydroxy-2-methylphenyl)ethan-1-one proceeded under standard conditions. Introduction of the nitrile was achieved through palladium catalyzed coupling of zinc cyanide with the triflate to afford 4-acetyl-3-methylbenzonitrile. Bromination of this material then provided 4-(2-bromoacetyl)-3-methylbenzonitrile which was employed in the batch synthesis of **1at** as shown in Scheme 4. The data for the initial biological evaluation of **1at** are included in Table 4, indicating that the compound exhibits submicromolar potency in both of the primary cellular assays.

Activity against NNRTI resistant virus is an important feature of a compound with promise for further development. Mutations at the two amino acid positions, Y181C and K103N, have been associated with resistance to most NNRTIs.⁴⁸ The docking of the DHPM **1at** containing the 4-cyanophenyl moiety into the crystal structures of Y181C, K103N RT bound to rilpivirine and two analogues (Fig. S2; see Supplementary Data) (PDB code 3BGR⁴⁷ and PDB codes 4I2Q, 4I2P⁴⁹) show that favorable interactions between Y181C, K103N and the DHPM would still be feasible. Consistent with our hypothesis, we found that addition of a methyl group on the cyanophenyl ring (as in **1at**) resulted in activity against NNRTI resistant virus (A17) while maintaining potency against wild type virus (see Table 10). Importantly, compound **1at** exhibits micromolar activity against the A17 strain whereas nevirapine is essentially inactive. Based on these results we expanded testing to include cell lines with another, highly clinically relevant, mutant form of RT (E138A) and were able to detect activity against this form of RT as well (Table ST1; see Supplementary Data). It is noteworthy that our approach allowed the rapid design of analogues with an activity profile matching that of nevirapine, a standard of care drug still commonly used in triple combination therapy.⁵⁰ Taken together, the results of these experiments suggest that the DHPMs are small molecule HIV replication inhibitors with the potential to treat resistant strains of virus.

3. Conclusion

Using the workflow shown in Fig. 6 we rapidly identified a DHPM derivative with activity against a deadly disease (AIDS) that has desirable drug-like properties as well as chemical features ideal for synthesis but for which the molecular target was unknown. Elucidation of the MOA was essential for advancement of this molecule. Flow chemistry methods were employed for rapid hit-to-lead optimization to provide novel HIV replication inhibitors, such as **11**, with cellular activity comparable with the clinically used drug NVP, and no detectable cytotoxicity. Using predictive *in silico* modeling combined with data from cellular and biochemical assays the compounds were shown to inhibit the viral RT enzyme. Our *in silico* model suggested that modifications to the DHPMs would provide inhibitors of drug resistant RT while maintaining activity against wild type RT. This led to the design, synthesis and testing of **1at**, a compound that, unlike NVP, inhibits the replication of the mutant HIV strains K103N and Y181C that contain amino acid variations associated with drugs exhibiting resistance to NNRTIs. Furthermore, evaluation of several active analogues in *in vitro* ADME assays suggest that these probe compounds may have promising drug-like properties. This is especially relevant because the penetration of drugs into CNS, gut and lymphoid tissue is an important feature of future HIV therapeutics.^{51–55} In summary, our

work has demonstrated an efficient approach to small molecule probe discovery that combines optimization using flow synthesis^{10,20,56} with biological testing and *in silico* modeling to achieve rapid and efficient MOA determination. Thus, we have exemplified a powerful strategy that should translate to other important therapeutics targets.

4. Experimental

All reactions were carried out using oven-dried glassware and conducted under a positive pressure of nitrogen unless otherwise specified. NMR spectra were recorded on a JEOL JNM-CS400 (400 MHz) spectrometer. All NMR samples were prepared using DMSO-*d*₆. High resolution mass spectrometry data were obtained with an Agilent Technologies 6224A time of flight mass spectrometer (MS-TOF) using electrospray ionization at the Sanford-Burnham Medical Research Institute (SBMRI). LC/MS analyses were carried out on a Shimadzu LC/MS 2010 Series LC System with a Kromasil 100 5 μ m C18 column (50 $\times$ 2.1 mmID). Preparative HPLC purifications were achieved using a Shimadzu SCL-10A system using either a Luna 5 μ m C18 column (100 $\times$ 30 mmID) or a YMC 10 μ m C18 column (150 $\times$ 20 mmID). Silica gel purifications were accomplished using a CombiFlash R_f system from Teledyne Isco using RediSep R_f pre-packed columns. All reagents as solvents were used as received from standard suppliers. Microfluidic experiments were conducted using a Syrris AFRICA[®] synthesis station.

4.1. General procedure for the continuous flow synthesis of DHPMs

All reactions were conducted in DMF under a positive back pressure of nitrogen at approximately 6.0 bar. Streams of the ketal-protected thioamide **3** (32.5 μ L/min, 0.45 M or 0.75 M, DMF, 1 equiv) and a solution of α -bromoketones **4** (32.5 μ L/min, 0.45 M or 0.75 M, DMF, 1 equiv) were mixed in a 250 μ L glass reactor heated to 150 $^{\circ}$ C (3.75 min). After exiting the chip, the combined flow (65.0 μ L/min) was introduced to a single stream (32.5 μ L/min, 0.54 M or 0.9 M, DMF, 1.2 equiv) of aldehydes **5** and ureas **6** in a 1000 μ L glass reactor heated to 200 $^{\circ}$ C (10 min). The reaction flow was then collected (1250 μ L) after passing through the back pressure regulator. Once cooled, the crude reaction mixtures were purified using reverse-phase preparative HPLC, lyophilized, and tested for anti-HIV activity. When measuring the efficiency of the process, the crude reaction mixtures were adsorbed onto silica gel, loaded onto a pre-packed silica gel column (12 g), and chromatographed using either hexanes: EtOAc or CH₂-Cl₂:MeOH.

The flow synthesis and characterization of dihydropyrimidine derivatives **1a–d**, **1f**, **1h**, **1j**, and **1k** was reported previously.¹⁰

4.1.1. Compound characterization data

4.1.1.1. 5-(4-(4-Chlorophenyl)thiazol-2-yl)-4-(3-hydroxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (1g): 60 mg (48%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.07 (d, *J* = 1.4 Hz, 1H), 8.17 (s, 1H), 8.09 (d, *J* = 8.7 Hz, 2H), 7.88 (d, *J* = 8.7 Hz, 2H), 7.70 (m, 1H), 7.25 (d, *J* = 8.7 Hz, 2H), 6.84 (d, *J* = 8.7 Hz, 2H), 5.45 (d, *J* = 2.8 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.1, 158.6, 152.3, 151.3, 138.5, 138.3, 136.0, 132.9, 128.0, 126.6, 118.9, 115.1, 113.8, 110.0, 103.9, 56.1, 18.0, one

hidden carbon. HRMS (ESI): m/z calcd for $C_{20}H_{17}ClN_3O_2S$ (M+H)⁺ 398.0725, found (M+H)⁺ 398.0720.

4.1.1.2. 4-(2-(4-(3-Hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1i): 56 mg (46%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.37 (s, 1H), 9.08 (d, J = 1.8 Hz, 1H), 8.20 (s, 1H), 8.11 (m, 2H), 7.89 (m, 2H), 7.73 (m, 1H), 7.09 (t, J = 7.8 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 6.77 (m, 1H), 6.60 (m, 1H), 5.43 (d, J = 3.2 Hz, 1H), 2.38 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.1, 157.4, 152.3, 151.4, 145.3, 138.6, 138.3, 132.8, 129.4, 126.6, 118.9, 117.5, 115.1, 114.5, 113.5, 110.0, 103.7, 56.6, 18.1. HRMS (ESI): m/z calcd for $C_{21}H_{17}N_4O_2S$ (M+H)⁺ 389.1067, found (M+H)⁺ 389.1055.

4.1.1.3. 4-(2-(4-(4-Hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1l): 16 mg (22%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.34 (s, 1H), 9.03 (d, J = 1.8 Hz, 1H), 8.16 (s, 1H), 8.09 (d, J = 8.7 Hz, 2H), 7.88 (d, J = 8.7 Hz, 2H), 7.65 (m, 1H), 7.14 (d, J = 8.2 Hz, 2H), 6.66 (d, J = 8.7 Hz, 2H), 5.36 (d, J = 3.2 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.3, 156.8, 152.2, 151.3, 138.3, 138.3, 134.3, 132.8, 128.0, 126.6, 118.9, 115.1, 115.0, 110.0, 103.9, 56.3, 18.0. HRMS (ESI): m/z calcd for $C_{21}H_{17}N_4O_2S$ (M+H)⁺ 389.1067, found (M+H)⁺ 389.1078.

4.1.1.4. 4-(2-(4-(4-Methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1m): 20 mg (27%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.35 (s, 1H), 9.04 (d, J = 1.4 Hz, 1H), 7.95 (s, 1H), 7.92 (d, J = 8.7 Hz, 2H), 7.70 (m, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.06 (t, J = 7.9 Hz, 1H), 6.59 (m, 1H), 6.79–6.75 (m, 2H), 5.41 (d, J = 3.7 Hz, 1H), 3.55 (s, 3H), 2.35 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.7, 157.4, 152.4, 151.9, 145.4, 138.1, 133.0, 132.4, 129.4, 128.8, 127.7, 117.5, 114.4, 113.5, 112.4, 103.9, 66.3, 56.6, 18.0. HRMS (ESI): m/z calcd for $C_{22}H_{19}N_4O_2S$ (M+H)⁺ 403.1223, found (M+H)⁺ 403.1201.

4.1.1.5. 4-(2-(4-(3-Methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1n): 26 mg (35%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.11 (d, J = 1.8 Hz, 1H), 8.19 (s, 1H), 8.10 (d, J = 8.7 Hz, 2H), 7.88 (d, J = 8.7 Hz, 2H), 7.77 (m, 1H), 7.21 (t, J = 8.2 Hz, 1H), 6.93–6.91 (m, 2H), 6.79 (m, 1H), 5.52 (d, J = 3.2 Hz, 1H), 3.67 (s, 3H), 2.36 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.9, 159.2, 152.4, 151.3, 145.5, 138.8, 138.2, 132.8, 129.7, 126.6, 118.9, 118.7, 115.2, 113.0, 112.4, 110.1, 103.7, 66.3, 56.4, 18.0. HRMS (ESI): m/z calcd for $C_{22}H_{19}N_4O_2S$ (M+H)⁺ 403.1223, found (M+H)⁺ 403.1307.

4.1.1.6. 4-(2-(4-(3-Hydroxy-4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1o): 17 mg (22%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.03 (d, J = 1.8 Hz, 1H), 8.91 (s, 1H), 8.17 (s, 1H), 8.11 (d, J = 8.7 Hz, 2H), 7.88 (d, J = 8.2 Hz, 2H), 7.65 (m, 1H), 6.95 (d, J = 1.8 Hz, 1H), 6.72–6.65 (m, 2H), 5.40 (d, J = 3.2 Hz, 1H), 3.67 (s, 3H), 2.36 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.2, 152.3, 151.3, 147.3, 146.0, 138.4, 138.3, 134.9, 132.8, 126.6, 118.9, 118.8, 115.3, 115.1, 111.5, 110.0, 103.8, 56.4, 55.5, 18.0. HRMS (ESI): m/z calcd for $C_{22}H_{19}N_4O_3S$ (M+H)⁺ 419.1172, found (M+H)⁺ 419.1180.

4.1.1.7. 4-(2-(6-Methyl-2-oxo-4-(4-phenoxyphenyl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1p): 29 mg (33%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.12 (d, *J* = 1.8 Hz, 1H), 8.19 (s, 1H), 8.09 (d, *J* = 8.2 Hz, 2H), 7.87 (d, *J* = 8.7 Hz, 2H), 7.78 (m, 1H), 7.37–7.31 (m, 4H), 7.10 (m, 1H), 6.94 (m, 4H), 5.52 (d, *J* = 3.2 Hz, 1H), 2.37 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.9, 156.5, 156.0, 152.3, 151.4, 139.0, 138.8, 138.2, 132.9, 130.0, 128.5, 126.6, 123.5, 118.9, 118.6, 118.5, 115.2, 110.0, 103.8, 56.0, 18.1. HRMS (ESI): *m/z* calcd for C₂₇H₂₁N₄O₂S (M+H)⁺ 465.1380, found (M+H)⁺ 465.1382.

4.1.1.8. 4-(2-(4-(4-(Benzyloxy)phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1q): 27 mg (30%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.08 (d, *J* = 1.8 Hz, 1H), 8.16 (s, 1H), 8.08 (d, *J* = 8.7 Hz, 2H), 7.87 (d, *J* = 8.7 Hz, 2H), 7.71 (m, 1H), 7.39–7.25 (m, 7H), 6.92 (d, *J* = 8.7 Hz, 2H), 5.45 (d, *J* = 3.2 Hz, 1H), 5.02 (s, 2H), 2.36 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.1, 157.7, 152.3, 151.3, 138.5, 138.3, 137.0, 136.3, 132.8, 128.4, 128.0, 127.8, 127.6, 126.6, 118.9, 115.1, 114.7, 110.0, 103.9, 69.1, 56.1, 18.0. HRMS (ESI): *m/z* calcd for C₂₈H₂₃N₄O₂S (M+H)⁺ 479.1536, found (M+H)⁺ 479.1537.

4.1.1.9. 4-(2-(6-Methyl-2-oxo-4-(4-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1r): 34 mg (40%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.18 (d, *J* = 1.8 Hz, 1H), 8.20 (s, 1H), 8.08 (d, *J* = 8.7 Hz, 2H), 7.87 (d, *J* = 8.7 Hz, 2H), 7.84 (m, 1H), 7.47 (d, *J* = 8.7 Hz, 2H), 7.31 (d, *J* = 8.2 Hz, 2H), 5.61 (d, *J* = 3.2 Hz, 1H), 2.35 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.6, 152.2, 151.3, 147.5, 143.4, 139.1, 138.2, 132.9, 128.7, 126.6, 121.1, 118.9, 115.3, 110.1, 103.6, 55.8, 18.1. HRMS (ESI): *m/z* calcd for C₂₂H₁₆F₃N₄O₂S (M+H)⁺ 457.0941, found (M+H)⁺ 457.0934.

4.1.1.10. 4-(2-(6-Methyl-2-oxo-4-(3-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1s): 39 mg (45%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.21 (s, 1H), 8.22 (s, 1H), 8.09 (d, *J* = 8.2 Hz, 2H), 7.88 (m, 3H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.38 (d, *J* = 7.8 Hz, 1H), 7.33 (s, 1H), 7.22 (d, *J* = 7.8 Hz, 1H), 5.66 (d, *J* = 3.2 Hz, 1H), 2.35 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.4, 152.2, 151.2, 148.3, 146.8, 139.3, 138.1, 132.8, 130.6, 126.6, 125.5, 119.9, 119.2, 118.9, 115.4, 110.1, 103.6, 55.9, 18.0. HRMS (ESI): *m/z* calcd for C₂₂H₁₆F₃N₄O₂S (M+H)⁺ 457.0941, found (M+H)⁺ 457.0946.

4.1.1.11. 3-(2-(4-(4-Hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1t): 20 mg (27%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.35 (s, 1H), 9.04 (d, *J* = 1.8 Hz, 1H), 8.33 (t, *J* = 1.4 Hz, 1H), 8.24 (m, 1H), 8.11 (s, 1H), 7.77 (m, 1H), 7.66–7.62 (m, 2H), 7.15 (d, *J* = 8.7 Hz, 2H), 6.68 (d, *J* = 8.2 Hz, 2H), 5.38 (d, *J* = 2.8 Hz, 1H), 2.37 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.2, 156.8, 152.2, 151.0, 138.2, 135.3, 134.4, 131.3, 130.5, 130.1, 129.3, 128.0, 118.8, 115.1, 113.7, 111.9, 103.9, 56.3, 18.0. HRMS (ESI): *m/z* calcd for C₂₁H₁₇N₄O₂S (M+H)⁺ 389.1067, found (M+H)⁺ 389.1061.

4.1.1.12. 3-(2-(4-(3-Hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1u): 19 mg (26%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.36 (s, 1H), 9.07 (d, *J* = 1.4 Hz, 1H), 8.33 (d, *J* = 1.4 Hz, 1H), 8.24 (d, *J* = 8.2 Hz, 1H), 8.13 (s, 1H), 7.77 (d, *J* = 7.8 Hz, 1H), 7.70 (m, 1H), 7.63 (t, *J* = 7.8 Hz, 1H), 7.07 (t, *J* = 7.8 Hz, 1H), 6.80–6.75 (m, 2H), 6.59 (dd, *J* = 8.2, 2.3 Hz, 1H), 5.42 (d, *J* = 3.2 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.0, 157.4, 152.3, 151.0, 145.3, 138.4, 135.2, 131.3, 130.5, 130.1, 129.4, 129.3, 118.8, 117.5, 114.4, 113.8, 113.5, 111.9, 66.3, 56.6, 18.0. HRMS (ESI): *m/z* calcd for C₂₁H₁₇N₄O₂S (M+H)⁺ 389.1067, found (M+H)⁺ 389.1058.

4.1.1.13. 3-(2-(4-(3-Hydroxyphenyl)-1,6-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1v): 26 mg (35%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.39 (s, 1H), 8.37 (t, *J* = 1.4 Hz, 1H), 8.27 (m, 1H), 8.21 (s, 1H), 7.90 (d, *J* = 3.7 Hz, 1H), 7.80 (m, 1H), 7.66 (t, *J* = 7.8 Hz, 1H), 7.08 (t, *J* = 7.8 Hz, 1H), 6.73–6.71 (m, 2H), 6.61 (m, 1H), 5.35 (d, *J* = 3.7 Hz, 1H), 3.17 (s, 3H), 2.56 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.8, 157.5, 153.4, 151.2, 144.4, 140.3, 135.1, 131.4, 130.5, 130.2, 129.5, 129.3, 118.7, 117.1, 114.5, 113.4, 112.0, 106.7, 55.9, 30.0, 16.6. HRMS (ESI): *m/z* calcd for C₂₂H₁₉N₄O₂S (M+H)⁺ 403.1223, found (M+H)⁺ 403.1212.

4.1.1.14. 4-(2-(4-(3-Hydroxyphenyl)-1,6-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1w): 21 mg (28%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.38 (s, 1H), 8.26 (s, 1H), 8.12 (d, *J* = 8.7 Hz, 2H), 7.91–7.89 (m, 3H), 7.07 (t, *J* = 7.8 Hz, 1H), 6.72–6.70 (m, 2H), 6.60 (m, 1H), 5.34 (d, *J* = 3.7 Hz, 1H), 3.16 (s, 3H), 2.56 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.9, 157.4, 153.3, 151.6, 144.4, 140.5, 138.2, 132.9, 129.5, 126.6, 118.9, 117.1, 115.8, 114.5, 113.3, 110.1, 106.7, 55.8, 30.0, 16.6. HRMS (ESI): *m/z* calcd for C₂₂H₁₉N₄O₂S (M+H)⁺ 403.1223, found (M+H)⁺ 403.1216.

4.1.1.15. 4-(2-(6-Methyl-2-oxo-4-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1x): 24 mg (34%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.03 (d, *J* = 1.8 Hz, 1H), 8.46 (m, 1H), 8.14 (s, 1H), 8.06–8.04 (m, 2H), 7.85–7.83 (m, 2H), 7.70–7.65 (m, 2H), 7.35 (d, *J* = 7.8 Hz, 1H), 7.19 (m, 1H), 5.56 (d, *J* = 3.2 Hz, 1H), 2.29 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.9, 161.9, 152.5, 151.3, 149.3, 139.3, 138.3, 136.8, 132.9, 126.6, 122.8, 121.4, 118.9, 115.0, 110.0, 103.0, 58.4, 18.2. HRMS (ESI): *m/z* calcd for C₂₀H₁₆N₅OS (M+H)⁺ 374.1070, found (M+H)⁺ 374.1063.

4.1.1.16. 4-(2-(6-Methyl-2-oxo-4-(pyridin-3-yl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1y): 27 mg (39%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.22 (d, *J* = 1.8 Hz, 1H), 8.59 (d, *J* = 2.3 Hz, 1H), 8.42 (dd, *J* = 4.6, 1.4 Hz, 1H), 8.22 (s, 1H), 8.09–8.07 (m, 2H), 7.90–7.85 (m, 3H), 7.72 (m, 1H), 7.34 (dd, *J* = 7.8, 4.6 Hz, 1H), 5.67 (d, *J* = 3.2 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.2, 159.1, 152.2, 151.3, 148.7, 148.3, 139.4, 139.3, 138.1, 134.3, 132.9, 126.6, 123.9, 118.9, 115.4, 110.1, 103.4, 54.4, 18.0. HRMS (ESI): *m/z* calcd for C₂₀H₁₆N₅OS (M+H)⁺ 374.1070, found (M+H)⁺ 374.1061.

4.1.1.17. 4-(2-(6-Methyl-2-oxo-4-(pyridin-4-yl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1z): 32 mg (46%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm)

9.22 (d, $J = 1.8$ Hz, 1H), 8.49 (d, $J = 5.5$ Hz, 1H), 8.23 (s, 1H), 8.09–8.06 (m, 2H), 7.92–7.86 (m, 3H), 7.33 (dd, $J = 4.6, 1.4$ Hz, 2H), 5.64 (d, $J = 3.7$ Hz, 1H), 2.33 (s, 3H). HRMS (ESI): m/z calcd for $C_{20}H_{16}N_5OS$ (M+H)⁺ 374.1070, found (M+H)⁺ 374.1061.

4.1.1.18. 4-(2-(4-(6-Fluoropyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ae): 33 mg (45%). ¹H NMR (400 MHz, DMSO- d_6): δ (ppm) 9.24 (d, $J = 1.8$ Hz, 1H), 8.22 (m, 2H), 8.09–8.06 (m, 2H), 7.93–7.85 (m, 4H), 7.13 (dd, $J = 8.5, 2.5$ Hz, 1H), 5.70 (d, $J = 3.2$ Hz, 1H), 2.34 (s, 3H). 164.1, 162.3 (d_{C-F}, $J = 234.8$ Hz), 152.1, 151.3, 146.0 (d_{C-F}, $J = 15.3$ Hz), 140.5 (d_{C-F}, $J = 8.6$ Hz), 139.5, 138.1, 137.9, 132.9, 126.6, 118.9, 115.5, 110.1, 109.8 (d_{C-F}, $J = 37.4$ Hz), 103.3, 53.5, 18.1. HRMS (ESI): m/z calcd for $C_{20}H_{15}FN_5OS$ (M+H)⁺ 392.0976, found (M+H)⁺ 392.0989.

4.1.1.19. 4-(2-(4-(5-Fluoropyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1af): 47 mg (64%). ¹H NMR (400 MHz, DMSO- d_6): δ (ppm) 9.27 (s, 1H), 8.46 (m, 2H), 8.24 (s, 1H), 8.08 (d, $J = 8.2$ Hz, 2H), 7.92 (s, 1H), 7.88 (d, $J = 8.2$ Hz, 2H), 7.60 (d, $J = 9.6$ Hz, 1H), 5.76 (d, $J = 2.8$ Hz, 1H), 2.36 (s, 3H). HRMS (ESI): m/z calcd for $C_{20}H_{15}FN_5OS$ (M+H)⁺ 392.0976, found (M+H)⁺ 392.0968.

4.1.1.20. 4-(2-(4-(2-Fluoropyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ag): 36 mg (49%). ¹H NMR (400 MHz, DMSO- d_6): δ (ppm) 9.26 (d, $J = 1.4$ Hz, 1H), 8.19 (s, 1H), 8.09 (s, 1H), 8.05 (d, $J = 8.2$ Hz, 2H), 7.90–7.85 (m, 4H), 7.29 (m, 1H), 5.85 (d, $J = 3.2$ Hz, 1H), 2.35 (s, 3H). HRMS (ESI): m/z calcd for $C_{20}H_{15}FN_5OS$ (M+H)⁺ 392.0976, found (M+H)⁺ 392.0986.

4.1.1.21. 4-(2-(4-(3-Fluoropyridin-4-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ah): 44 mg (59%). ¹H NMR (400 MHz, DMSO- d_6): δ (ppm) 9.31 (s, 1H), 8.53 (s, 1H), 8.35 (d, $J = 5.0$ Hz, 1H), 8.21 (s, 1H), 8.04 (d, $J = 8.2$ Hz, 2H), 7.89–7.87 (m, 3H), 7.40 (m, 1H), 5.94 (d, $J = 2.8$ Hz, 1H), 2.35 (s, 3H). HRMS (ESI): m/z calcd for $C_{20}H_{15}FN_5OS$ (M+H)⁺ 392.0976, found (M+H)⁺ 392.1009.

4.1.1.22. 4-(2-(4-(6-Chloropyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ai): 36 mg (47%). ¹H NMR (400 MHz, DMSO- d_6): δ (ppm) 9.27 (d, $J = 1.8$ Hz, 1H), 8.41 (d, $J = 2.3$ Hz, 1H), 8.23 (s, 1H), 8.08 (m, 2H), 7.88 (m, 3H), 7.78 (dd, $J = 8.2, 2.8$ Hz, 1H), 7.47 (d, $J = 8.2$ Hz, 1H), 5.71 (d, $J = 3.2$ Hz, 1H), 2.34 (s, 3H). ¹³C NMR (100 MHz, DMSO- d_6): δ (ppm) 164.0, 152.1, 151.3, 149.2, 148.5, 139.6, 139.1, 138.1, 132.9, 126.6, 124.6, 123.8, 118.9, 115.5, 110.2, 103.1, 53.6, 18.1. HRMS (ESI): m/z calcd for $C_{20}H_{15}ClN_5OS$ (M+H)⁺ 408.0680, found (M+H)⁺ 408.0690.

4.1.1.23. 4-(2-(4-(2-Chloropyridin-4-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ak): 26 mg (38%). ¹H NMR (400 MHz, DMSO- d_6): δ (ppm) 9.30 (d, $J = 1.8$ Hz, 1H), 8.35 (d, $J = 5.0$ Hz, 1H), 8.26 (s, 1H), 8.10–8.07 (m, 2H), 7.97 (m, 1H), 7.90–7.87 (m, 2H), 7.45 (d, $J = 1.4$ Hz, 1H), 7.36 (dd, $J = 5.0, 1.4$ Hz, 1H), 5.70 (d, $J = 3.7$ Hz, 1H), 2.34 (s, 3H). ¹³C NMR (100 MHz, DMSO- d_6): δ (ppm) 164.0, 156.5, 152.2, 151.3, 150.5, 140.1, 138.1, 132.9, 126.7, 122.2, 121.2, 118.9, 115.8, 110.2, 102.7, 55.1, 18.1. HRMS (ESI): m/z calcd for $C_{20}H_{15}ClN_5OS$ (M+H)⁺ 408.0680, found (M+H)⁺ 408.0675.

4.1.1.24. 4-(2-(4-(2,6-Dichloropyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1al): 35 mg (42%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.33 (d, *J* = 1.4 Hz, 1H), 8.22 (s, 1H), 8.06 (d, *J* = 8.2 Hz, 2H), 7.94 (m, 1H), 7.87 (d, *J* = 8.7 Hz, 2H), 7.84 (d, *J* = 8.2 Hz, 1H), 7.50 (d, *J* = 8.2 Hz, 1H), 6.00 (d, *J* = 2.8 Hz, 1H), 2.48 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 163.5, 151.4, 151.2, 147.9, 147.7, 141.1, 140.3, 137.9, 137.0, 132.7, 126.5, 124.5, 118.8, 115.5, 110.1, 101.9, 53.3, 18.1. HRMS (ESI): *m/z* calcd for C₂₀H₁₄Cl₂N₅OS (M+H)⁺ 442.0291, found (M+H)⁺ 442.0283.

4.1.1.25. 4-(2-(4-(6-Bromopyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1am): 40 mg (47%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.27 (d, *J* = 1.4 Hz, 1H), 8.40 (d, *J* = 2.3 Hz, 1H), 8.24 (s, 1H), 8.08 (d, *J* = 8.7 Hz, 2H), 7.88 (m, 3H), 7.68 (dd, *J* = 8.2, 2.8 Hz, 1H), 7.61 (d, *J* = 8.2 Hz, 1H), 5.69 (d, *J* = 3.2 Hz, 1H), 2.34 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 163.9, 152.0, 151.2, 149.1, 140.2, 139.6, 139.4, 138.1, 137.8, 132.9, 128.3, 126.6, 118.9, 115.5, 110.1, 103.0, 53.6, 18.1. HRMS (ESI): *m/z* calcd for C₂₀H₁₅BrN₅OS (M+H)⁺ 454.0156, found (M+H)⁺ 454.0158.

4.1.1.26. 4-(2-(6-Methyl-2-oxo-4-(6-(trifluoromethyl)pyridin-3-yl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ar): 45 mg (54%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.32 (d, *J* = 1.4 Hz, 1H), 8.79 (d, *J* = 1.8 Hz, 1H), 8.23 (s, 1H), 8.07 (d, *J* = 8.7 Hz, 2H), 8.00 (dd, *J* = 8.0, 2.1 Hz, 1H), 7.95 (m, 1H), 7.87 (d, *J* = 7.9 Hz, 3H), 5.83 (d, *J* = 3.2 Hz, 1H), 2.34 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 163.8, 152.0, 151.2, 148.9, 143.4, 139.9, 138.0, 136.3, 132.3, 126.6, 121.1, 118.9, 115.6, 110.2, 102.9, 53.9, 18.1. HRMS (ESI): *m/z* calcd for C₂₁H₁₅F₃N₅OS (M+H)⁺ 442.0944, found (M+H)⁺ 442.0932.

4.2. General procedure for the batch-mode synthesis of DHPMs

Reaction mixtures of ketal-protected thioamide **3** (50 mg, 0.246 mmol, 1 equiv) and α -bromoketones **4** (0.246 mmol) were prepared in 0.6 mL of DMF and heated to 150 °C for 5 min in sealed vials. After cooling, aldehydes **5** (0.295 mmol, 1.2 equiv) and ureas **6** (0.295 mmol, 1.2 equiv) were added and the reaction mixtures heated to 200 °C for an additional 10 min. Once cooled, the crude reaction mixtures were purified using reverse-phase preparative HPLC, lyophilized, and tested for anti-HIV activity. When measuring the efficiency of the process, the crude reaction mixtures were adsorbed onto silica gel, loaded onto a pre-packed silica gel column (12 g), and chromatographed using either hexanes:EtOAc or CH₂-Cl₂:MeOH.

4.2.1. Compound characterization data

4.2.1.1. 4-(3-Hydroxyphenyl)-6-methyl-5-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3,4-dihydropyrimidin-2(1H)-one (1e): 65 mg (61%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.37 (s, 1H), 9.08 (d, *J* = 1.4 Hz, 1H), 8.13 (s, 1H), 8.13 (d, *J* = 8.2 Hz, 2H), 7.78 (d, *J* = 8.2 Hz, 2H), 7.74 (m, 1H), 7.08 (t, *J* = 7.8 Hz, 1H), 6.80 (d, *J* = 7.8 Hz, 1H), 6.78 (m, 1H), 6.60 (m, 1H), 5.45 (d, *J* = 3.2 Hz, 1H), 2.37 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.0, 157.4, 152.4, 151.6, 145.4, 138.4, 137.9, 129.4, 127.9 (q_{C-F}, *J* = 32.6 Hz)

126.5, 125.7, 123.0, 117.5, 114.4, 114.3, 113.5, 103.9, 56.6, 18.0. HRMS (ESI): m/z calcd for $C_{21}H_{17}F_3N_3O_2S$ (M+H)⁺ 432.0988, found (M+H)⁺ 432.0978.

4.2.1.2. 4-(2-(6-Methyl-2-oxo-4-(quinolin-2-yl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1aa): 40 mg (51%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.29 (d, J = 1.4 Hz, 1H), 8.81 (d, J = 4.6 Hz, 1H), 8.59 (d, J = 7.8 Hz, 1H), 8.10 (s, 1H), 8.02 (dd, J = 8.2, 0.9 Hz, 1H), 7.95 (m, 1H), 7.81–7.69 (m, 6H), 7.44 (d, J = 4.6 Hz, 1H), 6.51 (d, J = 3.2 Hz, 1H), 2.44 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.0, 159.1, 151.7, 150.8, 149.1, 148.1, 139.9, 137.9, 132.5, 129.5, 129.4, 126.6, 126.4, 125.5, 124.3, 118.8, 115.3, 110.0, 103.1, 51.4, 18.1. HRMS (ESI): m/z calcd for $C_{24}H_{18}N_5OS$ (M+H)⁺ 424.1227, found (M+H)⁺ 424.1226.

4.2.1.3. 4-(2-(6-Methyl-2-oxo-4-(quinolin-4-yl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ab): 58 mg (56%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.19 (d, J = 1.8 Hz, 1H), 8.32 (d, J = 8.2 Hz, 1H), 8.17 (s, 1H), 8.10–8.07 (m, 2H), 7.98 (d, J = 7.3 Hz, 1H), 7.91–7.85 (m, 4H), 7.74 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.58–7.54 (m, 2H), 5.78 (d, J = 2.8 Hz, 1H), 2.38 (s, 3H). HRMS (ESI): m/z calcd for $C_{24}H_{18}N_5OS$ (M+H)⁺ 424.1227, found (M+H)⁺ 424.1211.

4.2.1.4. 4-(2-(4-(1H-Indol-2-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ac): 38 mg (38%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 10.78 (s, 1H), 9.16 (d, J = 1.8 Hz, 1H), 8.18 (s, 1H), 8.11–8.08 (m, 2H), 7.87–7.85 (m, 2H), 7.68 (m, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.00 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.90 (m, 1H), 6.23 (d, J = 2.3 Hz, 1H), 5.74 (d, J = 3.2 Hz, 1H), 2.39 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.1, 162.3, 152.4, 151.4, 140.7, 139.3, 138.3, 136.2, 132.8, 127.6, 126.6, 121.0, 119.9, 118.9, 115.1, 111.5, 110.0, 102.1, 99.0. HRMS (ESI): m/z calcd for $C_{23}H_{18}N_5OS$ (M+H)⁺ 412.1227, found (M+H)⁺ 412.1227.

4.2.1.5. 4-(2-(6-Methyl-4-(1-methyl-1H-indol-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ad): 21 mg (20%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.21 (d, J = 1.4 Hz, 1H), 8.15 (s, 1H), 8.05–8.03 (m, 2H), 7.92 (m, 1H), 7.86–7.84 (m, 2H), 7.44 (d, J = 8.2 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.08 (ddd, J = 8.2, 7.1, 1.1 Hz, 1H), 6.94 (ddd, J = 7.8, 6.9, 0.9 Hz, 1H), 6.27 (s, 1H), 5.89 (d, J = 3.7 Hz, 1H), 3.91 (s, 3H), 2.39 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.9, 162.3, 152.2, 151.3, 141.5, 139.2, 138.2, 137.2, 132.8, 126.8, 126.6, 121.2, 120.1, 118.9, 115.2, 110.0, 109.8, 102.6, 99.1, 48.6, 29.6, 18.0. HRMS (ESI): m/z calcd for $C_{24}H_{20}N_5OS$ (M+H)⁺ 426.1383, found (M+H)⁺ 426.1367.

4.2.1.6. 4-(2-(4-(2-Chloropyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1aj): 54 mg (54%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.27 (d, J = 1.4 Hz, 1H), 8.27 (dd, J = 4.6, 1.8 Hz, 1H), 8.19 (s, 1H), 8.05 (m, 2H), 7.89 (m, 1H), 7.85 (m, 2H), 7.78 (dd, J = 7.6, 2.1 Hz, 1H), 7.36 (dd, J = 7.8, 4.6 Hz, 1H), 5.99 (d, J = 3.2 Hz, 1H), 2.38 (s, 3H). HRMS (ESI): m/z calcd for $C_{20}H_{15}ClN_5OS$ (M+H)⁺ 408.0680, found (M+H)⁺ 408.0685.

4.2.1.7. 4-(2-(4-(6-Methoxypyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1an): 48 mg (48%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.17 (d, *J* = 1.8 Hz, 1H), 8.21 (s, 1H), 8.12 (d, *J* = 2.3 Hz, 1H), 8.11–8.08 (m, 2H), 7.90–7.87 (m, 2H), 7.77 (m, 1H), 7.64 (dd, *J* = 8.5, 2.5 Hz, 1H), 6.77 (d, *J* = 8.2 Hz, 1H), 5.58 (d, *J* = 2.8 Hz, 1H), 3.77 (s, 3H), 2.36 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.5, 163.0, 152.2, 151.3, 145.1, 139.0, 138.2, 137.7, 132.9, 132.6, 126.6, 118.9, 115.3, 110.7, 110.1, 103.5, 53.8, 53.1, 18.0. HRMS (ESI): *m/z* calcd for C₂₁H₁₈N₅O₂S (M+H)⁺ 404.1176, found (M+H)⁺ 404.1165.

4.2.1.8. 4-(2-(4-(5-Methoxypyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ao): 60 mg (48%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.21 (d, *J* = 1.8 Hz, 1H), 8.21 (s, 1H), 8.17 (s, 1H), 8.15 (d, *J* = 2.8 Hz, 1H), 8.11–8.08 (m, 2H), 7.89–7.85 (m, 3H), 7.28 (m, 1H), 5.67 (d, *J* = 3.2 Hz, 1H), 3.76 (s, 3H), 2.35 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.3, 155.4, 152.3, 151.3, 140.4, 140.3, 139.4, 138.2, 135.9, 132.9, 126.6, 119.3, 118.9, 115.5, 110.2, 103.3, 55.6, 54.3, 18.1. HRMS (ESI): *m/z* calcd for C₂₁H₁₈N₅O₂S (M+H)⁺ 404.1176, found (M+H)⁺ 404.1165.

4.2.1.9. 4-(2-(4-(2-Methoxypyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1ap): 56 mg (57%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.12 (d, *J* = 1.4 Hz, 1H), 8.15 (s, 1H), 8.05–8.02 (m, 3H), 7.88–7.86 (m, 2H), 7.55 (m, 1H), 7.51 (dd, *J* = 7.3, 1.8 Hz, 1H), 6.89 (dd, *J* = 7.3, 4.6 Hz, 1H), 5.79 (d, *J* = 3.2 Hz, 1H), 3.94 (s, 3H), 2.39 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.5, 160.7, 152.2, 151.3, 145.9, 139.7, 138.2, 136.2, 132.8, 126.5, 125.4, 118.9, 117.2, 115.0, 110.0, 101.9, 53.4, 51.0, 18.0. HRMS (ESI): *m/z* calcd for C₂₁H₁₈N₅O₂S (M+H)⁺ 404.1176, found (M+H)⁺ 404.1161.

4.2.1.10. 4-(2-(4-(6-Methoxypyridin-2-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1aq): 37 mg (37%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.10 (d, *J* = 1.4 Hz, 1H), 8.19 (s, 1H), 8.12–8.10 (m, 2H), 7.89–7.87 (m, 2H), 7.64 (s, 1H), 7.60 (dd, *J* = 7.3, 7.3 Hz, 1H), 6.94 (d, *J* = 6.9 Hz, 1H), 6.63 (d, *J* = 7.8 Hz, 1H), 5.51 (d, *J* = 3.2 Hz, 1H), 3.73 (s, 3H), 2.30 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 165.2, 163.2, 159.6, 153.3, 151.3, 139.6, 139.2, 138.4, 132.9, 126.6, 119.0, 115.0, 113.4, 110.1, 109.2, 103.2, 57.7, 52.8, 18.1. HRMS (ESI): *m/z* calcd for C₂₁H₁₈N₅O₂S (M+H)⁺ 404.1176, found (M+H)⁺ 404.1161.

4.2.1.11. 4-(2-(6-Methyl-2-oxo-4-(6-phenoxy)pyridin-3-yl)-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1as): 29 mg (33%). ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 9.21 (s, 1H), 8.19 (m, 1H), 8.11–8.06 (m, 3H), 7.93 (s, 1H), 7.86 (dd, *J* = 8.5, 2.1 Hz, 2H), 7.82–7.78 (m, 2H), 7.35 (t, *J* = 7.1 Hz, 2H), 7.17 (m, 1H), 7.05 (d, *J* = 8.2 Hz, 2H), 6.98 (d, *J* = 8.2 Hz, 1H), 5.63 (d, *J* = 2.8 Hz, 1H), 2.35 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 164.3, 162.5, 162.3, 153.8, 152.2, 151.3, 145.7, 139.3, 138.6, 138.1, 134.6, 132.8, 129.6, 126.6, 124.5, 121.2, 118.9, 115.3, 111.5, 110.1, 103.4, 53.6, 18.0. HRMS (ESI): *m/z* calcd for C₂₆H₂₀N₅OS (M+H)⁺ 466.1332, found (M+H)⁺ 466.1340.

4.2.1.12. 4-Acetyl-3-methylphenyl trifluoromethanesulfonate: To a solution of 1-(4-hydroxy-2-methylphenyl)ethan-1-one (67 mmol, 1 equiv) in pyridine (1 M) at 0 °C, trifluoromethanesulfonic anhydride (100 mmol, 1.5 equiv) was added. The reaction was allowed to warm to room temperature while stirring overnight. The reaction was quenched by pouring the mixture onto ice-cold water. The aqueous mixture was extracted with diethyl ether, and the organics were washed with water, 1 M HCl, water, and then brine. The organic phase was dried over Na₂SO₄ and concentrated *in vacuo*. The crude reaction mixture was adsorbed onto silica gel, loaded onto a pre-packed silica gel column, and chromatographed using hexanes: EtOAc (87%).

4.2.1.13. 4-Acetyl-3-methylbenzonitrile: A solution of 4-acetyl-3-methylphenyl trifluoromethanesulfonate (62 mmol) in anhydrous DMF (0.5 M) was degassed with N₂. To this solution Zn(CN)₂ (74.4 mmol, 1.2 equiv) and Pd(PPh₃)₄ (3.1 mmol, 0.05 equiv) were added and the reaction mixture degassed again. The reaction was heated at 80 °C for 15 h. The reaction mixture was dissolved in water and extracted with EtOAc. The organics were washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The crude reaction mixture was adsorbed onto silica gel, loaded onto a prepacked silica gel column, and chromatographed using hexanes: EtOAc (73%).

4.2.1.14. 4-(2-Bromoacetyl)-3-methylbenzonitrile: A solution of 4-acetyl-3-methylbenzonitrile (45 mmol, 1 equiv) in methanol (1 M) was chilled to 0 °C. Bromine (45 mmol, 1 equiv) was added drop-wise and the reaction mixture allowed to warm to room temperature as the red color disappeared. At this point, an equal volume of water (45 mL) was added, and the reaction mixture stirred for 15 h. The reaction was neutralized with solid NaHCO₃ and extracted with diethyl ether. The organics were washed with water, dried over Na₂SO₄ and concentrated *in vacuo*. The crude product mixture was utilized in the next step without further purification.

4.2.1.15. 3-Methyl-4-(2-(6-methyl-4-(1-methyl-1H-indol-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (1at): A mixture of ketal-protected thioamide **3** (1.67 mmol, 1 equiv) and 4-(2-bromoacetyl)-3-methylbenzonitrile (1.67 mmol, 1 equiv) was heated to 150 °C for 5 min in DMF (0.8 M). After cooling, a solution of 1-methyl-1H-indole-2-carbaldehyde (2 mmol, 1.2 equiv) and urea (2 mmol, 1.2 equiv) in DMF (0.8 M) was added and the reaction mixture heated to 200 °C for an additional 10 min. Once cooled, the crude reaction mixture was adsorbed onto silica gel, loaded onto a pre-packed silica gel column, and chromatographed using hexanes:EtOAc. ¹H NMR (400 MHz, (CD₃)₂SO) δ, ppm: 9.20 (s, 1H), 7.90 (s, 1H), 7.78 (s, 1H), 7.72 (m, 2H), 7.67 (m, 1H), 7.43 (dd, 2H, *J* = 12, 8 Hz), 7.10 (t, 1H, *J* = 7 Hz), 6.96 (t, 1H, *J* = 7 Hz), 6.27 (s, 1H), 5.85 (s, 1H), 3.87 (s, 3H), 2.42 (s, 3H), 2.31 (s, 3H). ¹³C NMR (400 MHz, (CD₃)₂SO) δ, ppm: 175.56, 163.70, 152.20, 151.53, 141.45, 138.89, 138.52, 137.18, 136.99, 134.33, 130.06, 129.58, 126.73, 121.13, 120.08, 119.12, 116.93, 110.10, 109.62, 102.59, 99.08, 48.70, 29.48, 20.48, 17.80. HRMS (ESI): *m/z* calcd for C₂₅H₂₁N₅OS 439.15, found (M+H)⁺ 440.1531.

4.3. Resolution of (R)-1i and (S)-1i

Baseline separation of the enantiomers of DHPM **1i** was achieved using the Chiral Cel OD-RH analytical HPLC column (Daicel/Chiral Technologies). First, **1i** (10 mg) was dissolved in DMSO (1 mL) and carefully filtered. Then, each isocratic injection was run using H₂O:CH₃CN (40:60) over 8 min. A flow rate of 0.8 mL/min was used and injection volumes of 40 µL could be reached without compromising baseline separation. After 20 injections, 2.6 mg of each isomer was isolated. Enantiomeric purity of the resolved stereoisomers was confirmed using this same procedure. Absolute configurations were assigned based on the combination of molecular docking studies of each enantiomer with the HIV-1 RT efavirenz binding pocket and biochemical assay inhibition results (Table ST2; see Supplementary Data ST2).

4.4. MAGI-CCR5 antiviral assay

MAGI-CCR5 cells (obtained from the NIH AIDS Research and Reference Reagent Program). Cells were seeded at a density of 1×10^4 cells/well into a 96-well plate. The following morning, the media was decanted and replenished with compounds diluted in DMSO and HIV_{Ba-L}, NL4-3, and A17 at an MOI of 10 TCID₅₀/mL. Compounds were evaluated at six concentrations (triplicate wells/-concentration). Identical uninfected plates were prepared for parallel cytotoxicity testing. The cultures were incubated for 48 h in an incubator maintained at 37 °C and 5% CO₂. Efficacy was assessed by galactosidase expression (Gal-screen™; Tropix, Bedford MA) and cytotoxicity by MTS staining (CellTiter Reagent, Promega).

4.5. PBMC assay

Fresh human PBMCs were isolated from screened donors, seronegative for HIV and HBV (Biological Specialty Corporation, Colmar, PA). Blood was processed for PBMC isolation by layering over Ficoll-Hypaque density gradient. Banded PBMCs were collected; washed in PBS and suspended at 1×10^6 cells/mL in RPMI 1640 supplemented with 15% Fetal Bovine Serum (FBS), 2 mM l-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 4 µg/mL Phytohemagglutinin (PHA; Sigma, St. Louis, MO; catalog #L1668). The cells were incubated for 48–72 h at 37 °C prior to use. After incubation, PBMCs were stimulated with 20 U/mL recombinant human IL-2 (R&D Systems Inc., Minneapolis, MN; catalog #202IL). Monocytes-derived-macrophages were depleted from the culture as the result of adherence to the tissue culture flask. PHA stimulated cells from at least two normal donors were pooled, diluted in fresh medium to a final concentration of 1×10^6 cells/mL, and seeded in the interior wells of a 96 well round bottom microplate at 50 µL/well (5×10^4 cells/well). For these studies, HIV_{Ba-L} was used at a final concentration of MOI $\cong$ 0.1/well. Cytotoxicity studies were performed using an MTS end-point (CellTiter Reagent, Promega). The PBMC cultures were maintained for six days following infection in a humidified incubator maintained at 37 °C, 5% CO₂. After this period, cell-free supernatant samples were collected for analysis of reverse transcriptase activity, and compound cytotoxicity was measured by addition of MTS staining.

4.6. RT biochemical assay

The HIV-1 RT (Protease derived) was used in experiments (obtained from the NIH AIDS Research and Reference Reagent Program; provided by Stuart Le Grice and Jennifer T Miller). RT activity was determined by the incorporation of radiolabeled deoxyribonucleotides into the newly synthesized DNA strand. The standard RT reaction mixture contained a synthetic homopolymeric template/primer [poly(rA)/oligo(dT)] or *in vitro* transcribed viral RNA derived from the HIV-1_{NL4-3} 5'-LTR region (nucleotide residues 454 to 652) and a primer complementary to the primer binding site (PBS, nucleotide residues 636 to 652), radiolabeled deoxyribonucleotide, dNTPs and RT. The reaction was carried out in a volume of 40 µl containing 50 mM Tris HCl, pH 7.8, 50 mM KCl, 5 mM MgCl₂, 1 mM DTT, 50 µM each of dATP, dCTP, dGTP, 50 nM dTTP, 1 µCi of [³H] dTTP (70–90 Ci/mM), and 5 nM template/primer. The reaction was initiated by the addition of 10 nM RT. For compound screening, serially diluted test articles were added to the reaction followed by the addition of RT. The reaction mixture was incubated at 37 °C for 1 h, then quenched by the addition of ice-cold trichloroacetic acid (TCA) to the final concentration of 10%. The plate was incubated at 4 °C for 1 h to precipitate the synthesized DNA, then rinsed 3-times with 10% TCA and 1 time with 70% ethanol. After addition of 25 µl scintillation fluid to completely dried wells, radioactivity is counted by MicroBeta scintillation counter.

Compounds were evaluated in triplicate, six-serial dilutions for each experiment. The IC₅₀ was calculated using the growth function in excel. Experiments were performed in triplicate and the average IC₅₀ and the standard deviation are reported.

4.7. Microsomal stability in vitro assay

Pooled rat liver microsomes (BD Biosciences, # 452701) were preincubated with test compounds at 37.5 °C for 5 min in the absence of NADPH. The reaction was initiated by addition of NADPH and incubated under the same conditions. The final incubation concentrations were 4 µM test compound, 2 mM NADPH, and 1 mg/mL (total protein) liver microsomes in phosphate-buffered saline (PBS) at pH 7.4. One aliquot (100 µL) of the incubation mixture was withdrawn at 15 min time points and combined immediately with 100 µL of ACN/MeOH. After mixing, the sample was centrifuged at approximately 13,000 rpm for 12 min. The supernatant was filtered and transferred into an autosampler vial and the amount of test compound was quantified using a Shimadzu LCMS 2010EV mass spectrometer. The change of the AUC (area under the curve) of the parent compound as a function of time was used as a measure of microsomal stability. Test compounds were run in duplicate with a positive control.

4.8. Plasma stability in vitro assay

A 20 µL aliquot of a 10 mM solution in DMSO of the test compound was added to 2.0 mL of heparinized rat plasma (Lampire, P1-150N) to obtain a 100 µM final solution. The mixture was incubated for 1 h at 37.5 °C. Aliquots of 100 µL were taken at 15 min intervals and diluted with 100 µL of MeOH/ACN. After mixing, the sample was centrifuged at approximately 13,000 rpm for 12 min. The supernatant was filtered and transferred into an autosampler vial and the amount of test compound was quantified using the Shimadzu

LCMS-2010EV system. The change of the AUC of the parent compound in function of time was used as a measure of plasma stability.

4.9. Parallel artificial membrane permeation assay (PAMPA)

A 96-well microtiter plate (Millipore, # MSSACCEPTOR) was filled with 300 μ L aqueous buffer solution (in general phosphate pH 7.2 buffer was used) and covered with a microtiter filterplate (Millipore, # MAIPNTR10) to create a sort of sandwich construction. The hydrophobic filter material was impregnated with a 10% solution of polar brain lipid extract in chloroform (Avanti) as the artificial membrane, and the organic solvent was allowed to completely evaporate. Permeation studies were started by the transfer of 150 μ L of a 100 μ M test compound solution on top of the filter plate. The maximum DMSO content of the stock solutions was <1.5%. In parallel, an equilibrium solution lacking a membrane was prepared using the exact concentrations and specifications but lacking the membrane. The concentrations of the acceptor and equilibrium solutions were determined using the Shimadzu LCMS-2010EV and AUC methods. The acceptor plate and equilibrium plate concentrations were rate ($\log P_e$) of the compounds. The $\log P_e$ values were calculated using the following equation:

$$\log P_e = \log \{C - \ln(1 - [\text{Drug}]_{\text{Acceptor}}/[\text{Drug}]_{\text{Equilibrium}})\}$$

$$C = (V_D \cdot V_A)/((V_D + V_A) \cdot \text{Area} \cdot \text{time})$$

In this equation, V_D (cm^3) is the donor volume (0.150 cm^3), V_A (cm^3) is the acceptor volume (0.300 cm^3), Area (cm^2) is the accessible filter area (0.168 cm^2), and time (s) is the incubation time. $[\text{Drug}]_{\text{Acceptor}}$ and $[\text{Drug}]_{\text{Equilibrium}}$ are concentration of the test drug for the sample (Acceptor) and reference (Equilibrium) solutions in the acceptor compartment.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Institutes of Health grant nos. AI078048, CA140427, HG005033, GM079590, and GM081261. The HIV-1 RT (Protease derived) was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH (catalog number 3555) from Stuart Le Grice and Jennifer T Miller. The authors would like to thank Marie K Mankowski and Chelsea R Laylock for their technical support.

References

1. Lansdon EB, Brendza KM, Hung M, et al. J Med Chem. 2010; 53:4295–4299. [PubMed: 20438081]
2. Haupt VJ, Schroeder M. Briefings Bioinf. 2011; 12:312–326.
3. Hu Y, Lounkine E, Bajorath J. AAPS J. 2014; 16:847–859. [PubMed: 24871342]
4. Hu Y, Bajorath J. Eur J Med Chem. 2014; 76:427–434. [PubMed: 24602788]
5. Hu Y, Bajorath J. F1000Research. 2014; 3:218. [PubMed: 25352982]
6. Schenone M, Dancik V, Wagner BK, Clemons PA. Nat Chem Biol. 2013; 9:232–240. [PubMed: 23508189]
7. Liu X, Zhu F, Ma XH, et al. Curr Med Chem. 2013; 20:1646–1661. [PubMed: 23410165]

8. Issa NT, Byers SW, Dakshanamurthy S. *Curr Topics Med Chem.* 2013; 13:2328–2336.
9. Issa NT, Kruger J, Byers SW, Dakshanamurthy S. *Expert Rev Clin Pharmacol.* 2013; 6:95–97. [PubMed: 23473587]
10. Pagano N, Herath A, Cosford NDP. *J Flow Chem.* 2011; 1:28–U63. [PubMed: 25237558]
11. Phucho IT, Nongpiur A, Tumtin S, Nongrum R, Nongkhlaw RL. *Rasayan J Chem.* 2009; 2:662–676.
12. Kappe CO. *Eur J Med Chem.* 2000; 35:1043–1052. [PubMed: 11248403]
13. Kim J, Ok T, Park C, et al. *Bioorg Med Chem Lett.* 2012; 22:2522–2526. [PubMed: 22374216]
14. Hutchinson AB, Farnham PG, Dean HD, et al. *J Acquired Immune Deficiency Syndromes.* 2006; 43:451–457.
15. Gebo KA, Fleishman JA, Conviser R, et al. *Aids.* 2010; 24:2705–2715. [PubMed: 20859193]
16. NIH. HIV/AIDS Fact Sheets. AIDSinfo; 2014. FDA-Approved HIV Medicines.
17. Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. *Antimicrob Agents Chemother.* 2012; 56:5000–5008. [PubMed: 22733071]
18. Wainberg MA. *Scientifica.* 2012; 2012:238278. [PubMed: 24278679]
19. Japour AJ, Mayers DL, Johnson VA, et al. *Antimicrob Agents Chemother.* 1993; 37:1095–1101. [PubMed: 8517697]
20. Pagano N, Heil ML, Cosford NDP. *Synth Stuttgart.* 2012; 44:2537–2546.
21. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. *Eur J Med Chem.* 2003; 38:223–232. [PubMed: 12667689]
22. Thompson MA, Aberg JA, Cahn P, et al. *JAMA.* 2010; 304:321–333. [PubMed: 20639566]
23. Grant RM, Lama JR, Anderson PL, et al. *N Engl J Med.* 2010; 363:2587–2599. [PubMed: 21091279]
24. C. Centers for Disease, Prevention. *MMWR Morbidity and mortality weekly report.* 2011; 60:65–68. [PubMed: 21270743]
25. Grosskurth H, Mosha F, Todd J, et al. *Lancet.* 1995; 346:530–536. [PubMed: 7658778]
26. C. Centers for Disease, Prevention. *MMWR. Morbidity and mortality weekly report.* 2006; 55:592–597. [PubMed: 16741495]
27. Connor EM, Sperling RS, Gelber R, et al. *N Engl J Med.* 1994; 331:1173–1180. [PubMed: 7935654]
28. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. *Science.* 2010; 329:1168–1174. [PubMed: 20643915]
29. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. *N Engl J Med.* 2012; 367:423–434. [PubMed: 22784038]
30. Jackson JB, Musoke P, Fleming T, et al. *Lancet.* 2003; 362:859–868. [PubMed: 13678973]
31. de Vincenzi I. Kesho Bora Study G. *Lancet Infect Dis.* 2011; 11:171–180. [PubMed: 21237718]
32. Coovadia HM, Brown ER, Fowler MG, et al. *Lancet.* 2012; 379:221–228. [PubMed: 22196945]
33. WHO. WHO. Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. World Health Organization; Geneva, Switzerland: 2012. 8
34. Chasela CS, Hudgens MG, Jamieson DJ, et al. *N Engl J Med.* 2010; 362:2271–2281. [PubMed: 20554982]
35. Klein R, Struble K. FDA. FDA; 2012. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus.
36. Das K, Bauman JD, Rim AS, et al. *J Med Chem.* 2011; 54:2727–2737. [PubMed: 21446702]
37. Das K, Clark AD Jr, Lewi PJ, et al. *J Med Chem.* 2004; 47:2550–2560. [PubMed: 15115397]
38. Janssen PA, Lewi PJ, Arnold E, et al. *J Med Chem.* 2005; 48:1901–1909. [PubMed: 15771434]
39. Jacobo-Molina A, Ding J, Nanni RG, et al. *Proc Natl Acad Sci U S A.* 1993; 90:6320–6324. [PubMed: 7687065]
40. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. *Science.* 1992; 256:1783–1790. [PubMed: 1377403]
41. Das K, Lewi PJ, Hughes SH, Arnold E. *Progress Biophys Mol Biol.* 2005; 88:209–231.

42. Braz VA, Barkley MD, Jockusch RA, Wintrode PL. *Biochemistry*. 2010; 49:10565–10573. [PubMed: 21090588]
43. Paris KA, Haq O, Felts AK, Das K, Arnold E, Levy RM. *J Med Chem*. 2009; 52:6413–6420. [PubMed: 19827836]
44. Das K, Martinez SE, Bauman JD, Arnold E. *Nat Struct Mol Biol*. 2012; 19:253–259. [PubMed: 22266819]
45. Thomsen R, Christensen MH. *J Med Chem*. 2006; 49:3315–3321. [PubMed: 16722650]
46. Le Grice SF, Gruninger-Leitch F. *Eur J Biochem/FEBS*. 1990; 187:307–314.
47. Das K, Bauman JD, Clark AD Jr, et al. *Proc Natl Acad Sci U S A*. 2008; 105:1466–1471. [PubMed: 18230722]
48. Wensing AM, Calvez V, Gunthard HF, et al. *Topics antiviral Med*. 2015; 23:132–141.
49. Johnson BC, Pauly GT, Rai G, et al. *Retrovirology*. 2012; 9:99. [PubMed: 23217210]
50. WHO. W.H. Organization. 18th WHO Model List of Essential Medicines. WHO; 2013.
51. Katlama C, Deeks SG, Autran B, et al. *Lancet*. 2013; 381:2109–2117. [PubMed: 23541541]
52. Kaul M, Garden GA, Lipton SA. *Nature*. 2001; 410:988–994. [PubMed: 11309629]
53. Robertson K, Liner J, Meeker RB. *J Neurovirol*. 2012; 18:388–399. [PubMed: 22811264]
54. Waters L, Fisher M, Winston A, et al. *Aids*. 2011; 25:65–71. [PubMed: 21099666]
55. Nguyen A, Rossi S, Croteau D, et al. *J Antimicrob Chemother*. 2013; 68:1161–1168. [PubMed: 23335197]
56. Herath A, Cosford NDP. *Beilstein J Org Chem*. 2017; 13:239–246. [PubMed: 28326132]

Fig. 1.
5-(Thiazol-2-yl)-3,4-dihydropyrimidin-2(1H)-one derivatives.

Fig. 2.
Testing funnel summarizing the biological assays employed in our study.

Fig. 3. Small molecule steric alignment based on the active conformation of rilpivirine (green) and compound **1i** (orange) (Discovery Studio 3.0; Accelrys, San Diego, CA).

Fig. 4.

Small molecule alignment focusing on pharmacophore features between rilpivirine (green) and the two stereo-isomers of compound **1i** (*R* = orange and *S* = purple; Discovery Studio 3.0; Accelrys, San Diego, CA). The VDW surface is shown in transparent gray. Yellow-green sphere: hydrophobic centroids, including aromatic rings. Blue spheres: hydrogen-bond donors. Purple spheres: hydrogen-bond acceptors. Blue-Purple spheres: hydrogen-bond acceptors and donors.

Fig. 5.

Molecular interaction between ripilvirine or (*R*)-**1i** and the NNRTI-site. Green shading represents hydrophobic region. Blue shading represents hydrogen bond acceptor. Cyan arrows represent hydrogen bonds (donor to acceptor). Grey parabolas represents accessible surface for large areas. Broken thick line around ligand shape indicates accessible surface. Size of residue ellipse represents the strength of the contact (Table ST3). 2D distance between residue label and ligand represents proximity (ICM, Molsoft, San Diego).

Fig. 6.
Schematic of the compound-centric approach.

Scheme 1. Microfluidic setup for the synthesis of DHPM analogues **1**.

Scheme 2.

“One-pot” batch synthesis of DHPMs **1**.

Scheme 3.

Batch synthesis of 4-(2-bromoacetyl)-3-methylbenzonitrile.

Scheme 4.

Batch synthesis of 3-methyl-4-(2-(6-methyl-4-(1-methyl-1H-indol-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile (**1at**).

Table 1

The antiviral activity of DHPMs **1a–k** ($R^2 = 3$ -hydroxyphenyl) against HIV-1 MAGI-CCR5 cells or PBMCs.

Entry	Product	R ¹	Yield (%) ^a	MAGI-CCR5 ^b				PBMC ^b			
				IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
1	1a		46 ^c	79 ± 7.4	>100	>100	1.3	37 ± 8.0	81 ± 8.7	76 ± 13.1	2.0
2	1b		43 ^c	66 ± 17.7	>100	>100	1.5	30 ^e	78 ^e	91 ^e	3.0 ^e
3	1c		45 ^c	68 ± 3.9	98 ± 0.8	89 ± 0.6	1.3	40 ± 6.9	85 ± 2.0	55 ± 7.4	1.4
4	1d		44 ^c	31 ± 6.9	80 ± 2.4	61 ± 1.7	2.0	16 ± 4.0	48 ± 11.6	65 ± 2.9	4.1
5	1e		61 ^d	5.2 ± 1.6	23 ± 0.5	40 ± 4.2	7.7	5.9 ± 1.3	18 ± 4.9	57 ± 1.7	9.7
6	1f		39 ^c	3.8 ± 0.6	50 ± 5.4	60 ± 1.4	16	8.0 ± 4.4	18 ± 6.7	58 ± 6.8	7.3
7	1g		48	1.9 ± 0.3	11 ± 2.8	55 ± 2.2	29	1.3 ± 0.2	4.1 ± 0.3	65 ± 2.3	50

Entry	Product	R ¹	Yield (%) ^a	MAGL-CCR5 ^b				PBM C ^b			
				IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
8	1 h		43 ^c	2.3 ± 2.9	1.5 ± 2.9	60 ± 0.8	26	3.6 ± 11.6	12 ± 4.4	56 ± 2.5	16
9	1 i		46	0.44 ± 0.03	2.1 ± 0.3	98 ± 2.1	223	0.19 ± 0.05	0.66 ± 0.07	84 ± 8.2	442
10	1 j		43 ^c	43 ± 1.1	84 ± 0.4	55 ± 0.6	1.3	13 ± 1.5	29 ± 1.8	47 ± 6.0	3.6
11	1 k		45 ^c	49 ± 2.8	>100	>100	2.0	NT	NT	NT	NT
12	NVP	–	–	0.04 ± 0.00	0.03 ± 0.00	10	250	0.06 ± 0.01	0.18 ± 0.03	10	167

IC₅₀ – compound concentration that reduces viral replication by 50%. IC₉₀ – compound concentration that reduces viral replication by 90%. TC₅₀ – compound concentration that reduces cell viability by 50%. Therapeutic Index (TI) = TC₅₀/IC₅₀. NT = not tested. NVP = nevirapine.

^a Isolated yields based on 1250 μL collection volumes and following silica gel chromatography.

^b An average of at least three independent experiments.

^c Flow synthesis previously reported.^{10,20}

^d Prepared using one-pot batch procedure, see Scheme 2 for details.

^e n = 1.

Table 2
The antiviral activity of DHPMs **1l–1w** against HIV-1 MAGI-CCR5 cells or PBMCs.

Entry	Product	Yield (%) ^a	R ²	R ¹	R ³	MAGI-CCR5 ^b				PBMC ^b			
						IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
1	1l	22		4-CNPh	H	0.04 ± 0.00	0.52 ± 0.15	>10.00	250	0.04 ± 0.00	0.12 ± 0.02	>100.00	2500
2	1m	27		4-CNPh	H	0.08 ± 0.01	0.37 ± 0.07	7.0 ± 1.3	88	0.12 ± 0.02	0.30 ± 0.03	76.6 ± 23.4	638
3	1n	35		4-CNPh	H	0.38 ± 0.04	1.8 ± 0.4	>100.00	263	0.56 ± 0.16	1.6 ± 0.5	>100.00	179
4	1o	22		4-CNPh	H	0.38 ± 0.06	37.8 ± 31.1	>100.00	263	0.15 ± 0.01	0.42 ± 0.06	>100.00	667
5	1p	33		4-CNPh	H	0.12 ± 0.02	0.62 ± 0.04	>10.00	83	0.53 ± 0.08	1.8 ± 0.4	>100.00	189
6	1q	30		4-CNPh	H	0.13 ± 0.01	0.75 ± 0.01	>10.00	77	0.21 ± 0.10	0.60 ± 0.30	>100.00	476
7	1r	40		4-CNPh	H	1.6 ± 0.3	7.6 ± 0.9	>100.00	63	8.6 ± 3.3	21.0 ± 6.8	>100.00	12

Entry	Product	Yield (%) ^a	R ²	R ¹	R ³	MAGL-CCR5 ^b				PBMC ^b			
						IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
8	1s	45		4-CNPh	H	2.4 ± 0.6	69.8 ± 30.2	>100.00	42	41.2 ± 21.9	>100.00	>100.00	2.4
9	1t	27		3-CNPh	H	4.4 ± 0.6	40.9 ± 1.5	69.6 ± 4.8	16	3.3 ± 1.2	10.2 ± 1.7	87.5 ± 12.5	27
10	1u	26		3-CNPh	H	8.7 ± 1.0	38.1 ± 2.7	51.8 ± 5.9	6.0	5.0 ± 1.4	15.1 ± 4.1	74.0 ± 16.2	15
11	1v	35		3-CNPh	Me	55.4 ± 2.4	89.2 ± 0.5	>100.00	1.8	14.5 ± 1.5	59.6 ± 4.6	64.2 ± 10.3	4.4
12	1w	28		4-CNPh	Me	2.4 ± 0.9	13.8 ± 6.2	>100.00	42	3.2 ± 0.1	8.5 ± 0.1	>100.00	31
13	NVP	–	–	–	–	0.04 ± 0.00	0.42 ± 0.03	10.0 ± 0.0	250	0.06 ± 0.01	0.19 ± 0.03	10.0 ± 0.0	167

IC₅₀ – compound concentration that reduces viral replication by 50%. IC₉₀ – compound concentration that reduces viral replication by 90%. TC₅₀ – compound concentration that reduces cell viability by 50%. TI = TC₅₀/IC₅₀. NT = not tested. NVP = nevirapine.

^aIsolated yields based on 1250 μL collection volumes and following silica gel chromatography.

^bAn average of at least three independent experiments.

Table 3

The antiviral activity of DHPMs **1x–1ad** ($R^1 = 4\text{-cyanophenyl}$) against HIV-1 MAGI-CCR5 cells or PBMCs.

Entry	Product	Yield (%)	R^2	MAGI-CCR5 ^c				PBMC ^c			
				IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
1	1x	34 ^a		2.0 ± 0.5	>100.00	>100.00	50	1.3 ± 0.5	4.4 ± 2.1	>100.00	77
2	1y	39 ^a		2.9 ± 0.1	>100.00	>100.00	35	1.5 ± 0.4	14.3 ± 5.5	>100.00	67
3	1z	46 ^a		1.4 ± 0.4	>100.00	>100.00	71	0.80 ± 0.20	34.6 ± 32.7	>100.00	125
4	1aa	51 ^b		3.8 ± 1.0	98.3 ± 1.7	>100.00	26	2.9 ± 0.9	10.5 ± 4.0	68.3 ± 22.1	24
5	1ab	56 ^b		1.5 ± 0.3	12.7 ± 3.6	>100.00	67	1.3 ± 0.2	5.5 ± 0.8	>100.00	77
6	1ac	38 ^b		2.1 ± 0.4	10.4 ± 1.4	50.5 ± 7.3	24	3.5 ± 1.8	10.8 ± 4.8	69.8 ± 16.5	20

Entry	Product	Yield (%)	R ²	MAGL-CCR5 ^c				PEMC ^c			
				IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
7	1ad	20 ^b		0.7 ± 0.1	3.7 ± 0.7	>100.00	143	1.1 ± 0.3	3.2 ± 0.5	>100.00	91
8	NVP	–	–	0.04 ± 0.00	0.42 ± 0.03	10.0 ± 0.0	250	0.06 ± 0.01	0.19 ± 0.03	10.0 ± 0.0	167

IC₅₀ – compound concentration that reduces viral replication by 50%. IC₉₀ – compound concentration that reduces viral replication by 90%. TC₅₀ – compound concentration that reduces cell viability by 50%. TI = TC₅₀/IC₅₀. NVP = nevirapine.

^a Isolated yields based on 1250 μL collection volumes and following silica gel chromatography.

^b Prepared using one-pot procedure, see Scheme 2 for details.

^c An average of at least three independent experiments.

Table 4

The antiviral activity of DHPMs **1ae–1at** ($R^1 = 4\text{-cyanophenyl}$) against HIV-1 MAGI-CCR5 cells or PBMCs.

Entry	Product	Yield (%) ^a	R ²	MAGI-CCR5 ^c				PBMC ^c			
				IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
1	1ae	45 ^a		1.1 ± 0.1	5.4 ± 0.7	>100	91	0.59 ± 0.13	2.0 ± 0.3	>100	170
2	1af	64 ^a		0.7 ± 0.1	>100.00	>100	143	0.53 ± 0.17	1.3 ± 0.6	>100	189
3	1ag	49 ^a		0.44 ± 0.07	2.6 ± 0.4	>100	227	0.26 ± 0.04	0.83 ± 0.03	>100	385
4	1ah	59 ^a		63.4 ± 20.0	>100.00	>100	1.6	NT	NT	NT	NT
5	1ai	47 ^a		0.48 ± 0.08	2.4 ± 0.6	>100	208	0.38 ± 0.06	0.94 ± 0.03	>100	263
6	1aj	54 ^b		2.2 ± 0.5	85.5 ± 14.5	>100	46	1.5 ± 0.7	8.8 ± 6.2	>100	67
7	1ak	38 ^a		3.2 ± 1.0	>100.00	>100	31	4.4 ± 1.4	44.5 ± 28.2	>100	23

Entry	Product	Yield (%) ^a	R ²	MAGI-CCRS ^c				PBMCC ^c			
				IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
8	1al	42 ^a		0.86 ± 0.02	5.8 ± 0.4	>100	116	1.9 ± 0.7	5.7 ± 1.5	99.1 ± 0.9	52
9	1am	47 ^a		0.35 ± 0.02	1.4 ± 0.3	>100	286	0.21 ± 0.09	0.57 ± 0.19	>100	476
10	1an	48 ^b		0.10 ± 0.02	0.58 ± 0.13	>10.0	100	0.12 ± 0.01	0.43 ± 0.09	>100	833
11	1ao	48 ^b		10.4 ± 3.0	>100.00	>100	9.6	NT	NT	NT	NT
12	1ap	57 ^b		3.8 ± 0.8	66.0 ± 20.4	>100	26	2.6 ± 0.6	7.3 ± 1.2	>100	39
13	1aq	37 ^b		1.6 ± 0.3	14.4 ± 3.0	>100	63	1.6 ± 0.7	5.9 ± 1.5	>100	63
14	1ar	54 ^a		1.1 ± 0.3	7.3 ± 0.8	>100	91	1.2 ± 0.8	4.6 ± 1.9	>100	83
15	1as	33 ^b		0.64 ± 0.04	2.8 ± 0.1	>100	156	1.2 ± 0.3	3.4 ± 0.8	67.5 ± 17.8	56

Entry	Product	Yield (%) ^a	R ²	MAGL-CCRS ^c				PEMC ^c			
				IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
16	1at	30 ^b		0.39 ± 0.05	1.9 ± 0.3	>100	256	0.65 ^d	2.17 ^d	>100 ^d	154
NVP	-	-	-	0.04 ± 0.00	0.42 ± 0.03	10.0 ± 0.0	250	0.06 ± 0.01	0.19 ± 0.03	10 ± 0.0	167

IC₅₀ – compound concentration that reduces viral replication by 50%. IC₉₀ – compound concentration that reduces viral replication by 90%. TC₅₀ – compound concentration that reduces cell viability by 50%. TI = TC₅₀/IC₅₀. NT = not tested. NVP = nevirapine.

^a Isolated yields based on 1250 μL collection volumes and following silica gel chromatography.

^b Prepared using one-pot batch procedure, see Scheme 2 for details.

^c An average of at least three independent experiments.

^d n = 1.

Table 5

In vitro ADME data for selected DHPMs.

Entry	Cpd	R ²	PAMPA (LogPe) ^a	Plasma Stability ^b (%)	Microsomal Stability ^b (%)
1	1i		-7.84 ± 0.22	88.46 ± 10.73	52.35 ± 0.71
2	1l		-7.82 ± 0.14	100.00 ± 8.50	100.00 ± 4.60
3	1m		-7.11 ± 0.06	95.97 ± 1.36	63.15 ± 4.43
4	1y		-7.50 ± 0.10	89.42 ± 2.93	75.55 ± 7.86
5	1ad		-7.05 ± 0.12	95.63 ± 4.19	62.87 ± 1.40
6	1ai		-7.40 ± 0.03	91.65 ± 2.56	63.40 ± 0.73
7	1ae		-6.24 ± 0.07	100.00 ± 6.37	49.38 ± 1.00

Entry	Cpd	R ²	PAMPA (LogPe) ^a	Plasma Stability ^b (%)	Microsomal Stability ^b (%)
8	1an		-7.25 ± 0.05	100.00 ± 18.70	69.42 ± 1.94
9	1am		-7.82 ± 0.05	98.29 ± 8.08	67.61 ± 1.35

^aPermeability is monitored by measuring the amount of compound that can diffuse through a polar brain lipid membrane to predict BBB permeability.

^bPercent remaining after incubation for 60 min. at 37 °C.

Table 6

Molecular steric alignment similarity between the stereoisomers of two DHPM analogues and the NNRTIs rilpivirine and etravirine in their active conformation¹ (Discovery Studio 3.0; Accelrys, San Diego, CA).

Compound	Rilpivirine	Etravirine
(<i>R</i>)-1i	0.807	0.776
(<i>S</i>)-1i	0.805	0.796
(<i>R</i>)-1an	0.820	0.780
(<i>S</i>)-1an	0.813	0.798

Table 7

DHPMs and inhibitory activity against HIV wildtype (NL4-3) and A17 (K103N, Y181C) virus in MAGI-CCR5 cells.

Compound	Virus	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
1l	NL4-3	0.06 ± 0.01	0.62 ± 0.09	46 ± 6.1	765
	A17	28 ± 1.4	95 ± 2.6		1.6
1m	NL4-3	0.05 ± 0.01	0.62 ± 0.04	5.5 ± 1.0	110
	A17	3.4 ± 0.1	24 ± 8.0		1.6
1ad	NL4-3	0.52 ± 0.15	5.0 ± 2.3	>100	192
	A17	>100	>100		1
1ae	NL4-3	1.1 ± 0.2	7.6 ± 0.2	>100	>91
	A17	>100	>100		NA
1am	NL4-3	0.50 ± 0.14	3.2 ± 1.0	>100	>200
	A17	>100	>100		1
1an	NL4-3	<0.32 ± 0.0	1.9 ± 0.9	>100	>313
	A17	>100	>100		1
1ar	NL4-3	0.86 ± 0.24	7.7 ± 1.1	>100	>116
	A17	>100	>100		NA
NVP	NL4-3	0.04 ± 0.0	0.54 ± 0.01	>10	>250
	A17	>10	>10		1

IC₅₀ – compound concentration that reduces viral replication by 50%. IC₉₀ – compound concentration that reduces viral replication by 90%. TC₅₀ – compound concentration that reduces cell viability by 50%. TI = TC₅₀/IC₅₀. NVP = nevirapine.

Table 8

Docking results from the stereoisomers of compounds **1i** and **1an** in the NNRTI binding site of HIV-RT from the rilpivirine structure¹ (PDB code 3MEE (Molegro MVD, Aarhus, Denmark)).

Compound	ReRank Score
(<i>R</i>)-1i	−132.1
(<i>S</i>)-1i	−94.5
(<i>R</i>)-1an	−136.4
(<i>S</i>)-1an	−83.1

DHPM enantiomers (*R*)-**1i** and (*S*)-**1i** and their respective inhibitory activity against HIV-1 reverse transcriptase (RT).

Table 9

Product	PBMC antiviral assay			RT biochemical IC ₅₀ (μM) ± SD	
	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI	
Nevirapine	0.04 ± 0.003	0.17 ± 0.12	>10	>250	0.18 ± 0.01
(<i>R</i>)- 1i	0.11 ± 0.05	0.42 ± 0.24	>100	>909	0.60 ± 0.09
(<i>S</i>)- 1i	22 ± 1.5	77 ± 3.4	>100	>4.5	Not active

Table 10

DHPMs **1ad** and **1at** and inhibitory activity against HIV wildtype (NL4-3) and A17 (K103N, Y181C) in MAGI-CCR5.

Compound	Virus	IC ₅₀ (μM)	IC ₉₀ (μM)	TC ₅₀ (μM)	TI
1ad	NL4-3	0.52 ± 0.16	5.0 ± 2.3	>100	>192
	A17	>100	>100	>100	1
1at	NL4-3	0.39 ± 0.05	4.8 ± 0.6	>100	>256
	A17	6.4 ± 0.6	>100	>100	>15.6
NVP	NL4-3	0.07 ± 0.03	0.60 ± 0.07	>10	>143
	A17	>10	>10	>10	1

IC₅₀ – compound concentration that reduces viral replication by 50%. IC₉₀ – compound concentration that reduces viral replication by 90%. TC₅₀ – compound concentration that reduces cell viability by 50%. TI = TC₅₀/IC₅₀. NVP = nevirapine.